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SOMMARIO 
INTRODUZIONE  
Le β-talassemie sono una delle malattie genetiche più frequenti in tutto il mondo 
con 270 milioni di portatori e 350.000 nuovi nati affetti all’anno.  
Questa malattia è geneticamente caratterizzata dalla perdita di produzione della 
catena β globinica dell'emoglobina adulta, dovuta a diverse mutazioni nel gene 
della β-globina. Poiché il gene beta è espresso su entrambi i cromosomi 11, 
possiamo avere due differenti tipi (e con differente gravità) di beta talassemia a 
seconda dell’assenza di entrambi o di un solo gene della beta globina: nel primo 
caso si ha la β talassemia MAJOR o trasfusione dipendente, nel secondo caso si 
ha la β talassemia MINOR o INTERMEDIA trasfusione indipendente. I nostri studi 
si concentrano su quest’ultima.  
L'assenza della catena β globina comporta diverse conseguenze per l'organismo 
come:  
- Eritropoiesi inefficace  
- Il sovraccarico di ferro  
- Il danno ossidativo  
Finora sono stati condotti molti studi in diversi campi (genomico, proteomico e nel 
metabolismo ferro) per garantire una maggiore comprensione di questa malattia. 
Recentemente si è scoperta una nuova proteina che potrebbe essere un eventuale 
regolatore o responsabile del sovraccarico di ferro nella β - talassemia; questa 
molecola è la ferroportina.  
La Ferroportina (FPN) è l'unico esportatore di ferro finora conosciuto. Essa è 
espressa in diversi tipi di cellule, tra cui gli enterociti duodenali, gli epatociti, i 
macrofagi e gli eritroblasti.  
Pochi anni fa, è stata segnalata l'esistenza di due trascritti alternativi della FPN con 
o senza le Iron Responsive Elements (IRE) sul loro promotore (FPN1A e FPN1B 
rispettivamente). L'espressione delle diverse isoforme della ferroportina nonché i 
meccanismi che la regolano nelle cellule eritroidi della β talassemia non-
trasfusione dipendente (NTDT) non sono ancora noti.  
 
SCOPO  
Studiare il profilo di espressione delle due isoforme della ferroportina durante il 
differenziamento eritroide in colture controllo e di NTDT e chiarire i meccanismi che 
regolano la loro espressione.  
 
MATERIALI E METODI 
Per questi studi è stato usato un modello di eritropoiesi in vitro derivato da cellule 
CD34
+
 provenienti da sangue periferico di volontari sani (controllo) e pazienti 
NTDT. Il profilo dell'espressione genica delle due isoforme (FPN1A e FPN1B) è 
stato valutato allo stadio basale (giorno 0) e al giorno 7 e 14 della cultura (stadio di 
pro eritroblasti e di eritrociti ortocromatici rispettivamente) mediante la tecnica di 
real-time PCR (2
-dCt
). La percentuale relativa di ogni isoforma è stata calcolata 
sulla base dell’espressione della ferroportina totale (FPN1A + FPN1B). La 
concentrazione di ferro intra and extracellulare è stata analizzata utilizzando un kit 
di Ferro Assay (Biovision). In esperimenti indipendenti, colture di controllo e NTDT 
sono state trattate con: ferro (Ferro Ammonio Citrato [FAC] 100μM), Desferal 
(DFO, 4μM), protoporfirina (SNPP IX 50-20μM), eme (Emina 20-10μM) o perossido 
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di idrogeno (H2O2 0,1mM) per indagare su un possibile ruolo di questi composti 
nella regolazione della ferroportina. L’espressione della FPN è stata valutata al 
14esimo giorno in condizioni standard e nei trattati mediante la tecnica di real-time 
PCR (2
-ddCt
; cellule non trattate utilizzate come calibratore).  
 
RISULTATI  
L'espressione ferroportina aumenta durante il differenziamento eritroide, 
raggiungendo il livello massimo di espressione allo stadio di eritroblasti (giorno 14 
di coltura) sia nel controllo sia negli NTDT. La FPN1A è l'isoforma più espressa in 
entrambe le condizioni. La sua espressione è più elevata negli stadi iniziali e finali 
dell’eritropoiesi (giorno 0 e 14), mentre l'espressione della FPN1B è maggiore nella 
fase intermedia di differenziamento eritroide (giorno 7). Degno di nota, 
l'espressione della FPN1B, anche se inferiore rispetto alla 1A, è significativamente 
maggiore nelle culture NTDT rispetto ai controlli, in particolare al giorno 14. La 
concentrazione di ferro intracellulare è diminuita in modo significativo durante il 
differenziamento eritroide (dal giorno 7 al giorno 14), sia nei controlli sia negli 
NTDT, tuttavia, al giorno 7 (stadio di eritroblasti) i livelli di ferro nelle culture NTDT 
sono notevolmente inferiori rispetto ai controlli. L'aggiunta di FAC, DFO, SnPP IX 
ed Emina nei controlli e nelle colture di NTDT non ha modificato l'espressione della 
ferroportina rispetto ai non trattati. L’H2O2 aggiunto ai controlli aumenta 
l'espressione di entrambe le isoforme della ferroportina (FPN1A: cellule non 
trattate: 1; H2O2: 1.33 FPN1B: cellule non trattate: 1; H2O2: 2.04). I livelli di ferro 
intra ed extracellulari riflettono i risultati genetici: c'è stato un aumento di ferro 
extracellulare causa di un aumento di espressione FPN.  
 
CONCLUSIONI  
L'espressione della ferroportina aumenta durante il differenziamento eritroide sia 
nei controlli sia nelle culture NTDT, suggerendo il suo ruolo nell’esportare il ferro 
intracellulare in eccesso. In entrambe le condizioni, la FPN1A è l'isoforma più 
espressa. Tuttavia, l'espressione dell’isoforma 1B non responsiva al ferro, anche 
se minore rispetto a FPN1A, è significativamente maggiore nei NTDT rispetto ai 
CTRL. In colture di controllo, l’espressione della FPN, ed in particolare 
dell’isoforma 1B, sembra essere regolata dall’aggiunta di H2O2. Questi dati 
suggeriscono che lo stress ossidativo, particolarmente elevato nelle NTDT, 
potrebbe essere uno dei principali regolatori dell’espressione dell’isoforma 1B, 
generando così un’importante esportazione di ferro dalle cellule NTDT. 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
ABSTRACT 
INTRODUCTION 
β-Thalassemias are one of the most frequent genetic disorders worldwide with 270 
million of carriers and 350.000 affected new-borns per year. 
This disease is genetically characterized by the loss of production of the β globin 
chain of the adult haemoglobin, due to several mutation within the beta globin 
gene. Since the beta gene is expressed on both the chromosomes 11, we can 
have two different type (and severity) of beta thalassemia depending on the 
absence of both or just one beta gene: in the first case we have the β thalassemia 
MAJOR transfusion dependent, in the second case we have the β thalassemia 
MINOR or INTERMEDIA, transfusion independent. Our studies are focused on the 
last one. 
The absence of the β globin chain implies different consequences for the organism 
like as: 
- Ineffective erythropoiesis 
- Iron overload 
- Oxidative damage 
Many studies have been conducted so far in different fields (genomic, protein 
expression and regulation, iron metabolism) in order to guarantee a major 
comprehension of this disease. Recently a new protein came out as a possible 
regulator/responsible for the iron overload in β thalassemia; this molecule is the 
FERROPORTIN. 
Ferroportin (FPN) is the only know iron exporter protein. It is expressed in different 
cell types including duodenal enterocytes, hepatocytes, macrophages and 
erythroblast cells. 
Few years ago it has been reported the existence of two alternative transcripts of 
FPN with or without an iron – responsive element (IRE) on their promoter (FPN1A 
and FPN1B respectively). The expression of the different ferroportin isoforms as 
well as the mechanisms regulating their expression in erythroid cells in non-
transfusion dependent β thalassemia syndromes (NTDT) are not known yet. 
 
AIM 
To investigate the expression profile of ferroportin isoforms during erythroid 
differentiation in control and NTDT cell cultures and to elucidate the mechanisms 
regulating their expression. 
 
MATERIALS AND METHODS 
An in vitro model of erythropoiesis derived from human peripheral CD34+ cells 
from healthy volunteers (control) and NTDT patients was used. The expression 
profiling of FPN isoforms (FPN1A and FPN1B) was evaluated at baseline (day 0) 
and at day 7 and 14 of culture (pro erythroblasts and orthochromatic erythroblasts 
stage respectively) by real−time PCR (2
−dCt
). The relative percentage of each 
isoform was calculated based on total ferroportin expression (FPN1A+FPN1B). 
The intracellular iron concentration was analyzed by using an Iron Assay Kit 
(Biovision). In independent experiments, control and NTDT cultures were treated 
with iron (Ferric Ammonium Citrate [FAC] 100µM), Desferal (DFO, 4µM), 
protoporfirin (SnPP IX 50-20µM), heme (Hemin 20-10µM) or hydrogen peroxide 
(H2O2 0.1mM) to investigate a possible role of these compounds in ferroportin 
IV 
 
regulation; FPN expression was evaluated at day 14 in standard and treated 
conditions by real−time PCR (2
−ddCt
; untreated cells used as calibrator). 
 
RESULTS 
The ferroportin expression increased during erythroid differentiation; with the 
highest level at the end of erythroblasts stage (day 14 of cultures) both in control 
and NTDT cultures. The FPN1A was the more expressed isoform in both 
conditions. Its expression was higher at the initial and final steps of erythropoiesis 
(day 0 and 14), while FPN1B expression was higher at the intermediate 
erythroblast stages (day 7). Noteworthy, the FPN1B expression, although lower 
compared to FPN1A, was significantly higher in NTDT cultures than in control 
ones, particularly at day 14. The intracellular iron concentration decreased 
significantly during erythroid differentiation (from day 7 to day 14) both in control 
and NTDT cultures, however, at day 7 (early erythroblasts stage) the iron levels in 
NTDT cultures were notably lower than in controls. The addition of FAC, DFO, 
SnPP IX and Hemin in control and NTDT cultures did not modify the ferroportin 
expression compared to untreated. H2O2 added to control cells increased the 
expression of both ferroportin isoforms (FPN1A: untreated cells: 1; H2O2: 1.33. 
FPN1B: untreated cells: 1; H2O2: 2.04). The intra and extracellular iron levels 
reflected the genetic results: there was an increase of extracellular iron due to an 
increase of FPN expression. 
 
CONCLUSIONS 
The ferroportin expression increases during erythroid differentiation either in control 
than in NTDT cultures, suggesting its role in exporting the excess intracellular iron. 
In both conditions, the FPN1A is the more expressed isoform. However, the 
expression of the non−iron responsive FPN1B isoform, although lower compared 
to FPN1A, is significantly higher in NTDT than in control conditions. In control 
cultures, FPN expression, and particularly the FPN1B isoform, seems to be up 
regulated by H2O2 addition. These data suggest that the oxidative stress, notably 
higher in NTDT conditions, could be one of the major regulator of FPN1B 
expression, with a major iron export from NTDT erythroblast cells.  
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INTRODUCTION 
CHAPTER 1: THE IRON METABOLISM 
1.1 The Iron 
Iron is a significant and extremely important molecule for all the organisms 
survival since is a heme and myoglobin component, and is involved in 
numerous metabolic reactions (such as: ossido/reduction, respiratory chain, 
DNA synthesis). Its characteristics have a certain ambiguity because one 
side is observed the importance for the survival, on the other hand the 
ability to react with oxygen, causing the production of free radicals and thus 
be toxic to tissues.  
This reaction, called Fenton reaction, is reported below: 
Fe3+ + H2O2 → Fe
2+ + OOH· + H+ 
In solution, the iron may have two oxidation states: Fe (II) or Fe 2+, and Fe 
(III), or Fe 3+; is poorly soluble at physiological pH, especially when it is in 
the oxidized form Fe (III); then the organisms had to obtain various proteins 
capable of transporting the ion in biological fluids and across cell 
membranes and to store it in the tissues in a non-toxic form and easily 
metabolizable.  
In physiological conditions, an adult body contains an average of 1.8 to 3.5 
grams of iron that could be split up in a functional compartment represented 
by haemoglobin (about 3 grams), mioglobin (100-150 milligrams) and 
intracellular enzymes (8-10 milligrams), and another compartment of 
deposit represented by ferritin (300-1000 milligram) (Figure 1.1).  
The heme content iron is continuously recycled and recovered through 
phagocytosis by the cycle of senescent red blood cells that are degraded 
by macrophages forming part of the reticuloendothelial splanchnic. This 
process allows the recovery of about 25-30 mg of iron daily, the quantity 
corresponding to that required to ensure erythropoiesis. 
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Intestinal absorption is the only way to introduce the ion in the body and is 
a process closely and finely tuned; at the level of the duodenal villi are 
absorbed daily about 1-2mg of iron. The elimination instead takes place 
through processes of epithelial desquamation, loss of blood, menstruations, 
all mechanisms not subjected to homeostatic regulation.  
 
Figure 1.1 : Iron Absorption, Distribution and Elimination through the 
Organism 
 
Source: Andrews NC. New England Journal of Medicine 1999; 1986-1995. 
 
1.2  The Intestinal Absorption of Iron  
Iron absorption is related to three main factors: 1) the content of iron in the 
diet: it is normally absorbed 5-10% of the iron present in food; 2) the 
bioavailability of the metal: the heme iron is more easily absorbed than non-
heme, whose absorption can be influenced by several factors in a negative 
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(phosphates and tannates), or in a positive sense (ascorbic acid); 3) the 
integrity of the mechanisms of iron uptake from the intestinal lumen to the 
enterocyte and the transportation from the latter to the bloodstream. 
Intestinal absorption is limited to the duodenum, the cells responsible for 
that are the enterocytes, placed on the surface of villus. The iron enters into 
the cell through the apical membrane and is transferred to the basal side 
before being exported to the plasma through the carrier called Ferroportin. 
Not all of the iron is introduced into the bloodstream, part of it remains into 
the enterocyte, bound to ferritin and it will be removed during the process of 
exfoliation of the intestinal wall. 
The first step for the iron absorption is the reduction: there is the passage 
from the ferric state to the ferrous thanks to the action of a reductase 
placed on the apical membrane of the enterocyte. Once reduced (Fe (II)), 
the iron enters into the cell through the transporter Nramp2 / DMT1 (its 
synthesis is strongly enhanced by iron depletion).  
Once reached the vascular bed, the iron binds to transferrin (Tf), the main 
transport protein, which provides the transfer of iron to various tissues. It is 
very important that the iron does not remain free in the cells or in the 
bloodstream, it has to be bound to proteins because free iron participates in 
a reaction that generates oxygen free radicals damaging the tissues. 
 
1.3  The Hematic Iron Recycling  
Most of the iron in the body is bound to haemoglobin and the phagocytosis 
of senescent erythrocytes by macrophages guarantees an efficient 
recycling of iron.  
Daily, about 20-25 mg of iron are retrieved by this route of recycling and 
they will then be used for the production of new haemoglobin during the 
erythropoiesis in the bone marrow. (Figure 1.2)  
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Macrophages responsible of the degradation of senescent red blood cells 
are found mainly in the spleen, bone marrow and in the Kupffer cells. 
During their stay in the bloodstream (about 120 days), red blood cells 
undergo biochemical changes in the level of their membrane: 
externalization of phosphatidyl - serine, lipoprotein peroxidation, loss of 
sialic acid residues and antigen expression of senescence that are signals 
for macrophages ranging so to identify the cells that need to be degraded 
by a process of phagocytosis.  
The heme group is destroyed and the iron bound to it is released into the 
cytoplasm of the monocyte, the ion can now take different paths: be stuck 
to the ferritin and remain within the cell, or to come out from it by the 
ferroportin action and then be picked up by the plasmatic  transferrin.  
 
Figure 1.2 : Hematic Iron Recycling  
 
Source: Pietrangelo A. ; “Hereditary hemochromatosis--a new look at an old disease.” N 
Engl J Med 2004  
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1.4  The Intracellular Iron Homeostasis: the IRE/IRP System 
The synthesis of key proteins involved in iron metabolism, its transport, 
storage and use is controlled at the post-transcriptional level through the 
intracellular iron. This adjustment depends on the interaction between 
cytoplasmic proteins called "Iron Regulation Proteins" (IRPs), which act as 
sensors of the iron, and the "Iron Responsive Elements" (IREs), which are 
highly conserved motif of 30 nucleotides at the level of '3 'end or 5' mRNA 
having a steem - loop or ring conformation. (Figure 1.3)  
The loop is characterized by a consensus sequence as follow: 5 '- 
CAGUGN - 3' which will be recognized by the IRP.  
Single IREs are present at the 5' non-coding region of the mRNA of the H 
or L subunit ferritin and ferroportin. A single IRE was found the 3' end of the 
mRNA of the protein responsible for the transport of iron (transferrin 
receptor TfR1 and DMT1). There are two distinct forms of IRP: IRP1 and 
IRP2 which have a high affinity for IREs regions. The entry of the iron in the 
cell causes a change of the conformation of IRP1 through the acquisition of 
a cluster iron - sulfur (4Fe-4S) and degradation of IRP2 due to oxidation.  
If an IRP should recognize the IRE of ferritin mRNA, this bond would 
prevent the translation of the protein as it would be impossible for the 
ribosome binding to the 5' of the transcript; if the IRP binds the 3' end, this 
would ensure a better stabilization of the polyA tail resulting in an increased 
translation of the gene.  
This  post – transcriptional regulation iron - modulated allows to modify the 
cell's ability to absorb the ion according to the need. 
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Figure 1.3 : The Action of IRE/IRP 
 
Source: Valenti L. presentation: “Metabolismo del Ferro”2010 
 
1.5  The Iron Homeostasis at the Organism Level: the Role of Hepcidin 
and Ferroportin. 
As already mentioned, there is no specific mechanism by which the body 
can eliminate the iron absorbed in excess; the iron overload can be avoided 
through the control of intestinal absorption and the macrophagic recycling 
ways.  
In 2001 it was discovered a hepatic protein with antimicrobial function 
called hepcidin (hepcidin, hep = hepatocyte, idine = indicates the 
antimicrobial activity).  
Hepcidin is a hepatic peptide hormone, its gene contains three exons and 
encodes a pro peptide of 84 amino acids having a signal peptide and a site 
for cutting by a furin that ensures the production of a functional protein.  
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Hepcidin is one of the acute phase proteins, it has a structure of 25 amino 
acids containing 8 cysteine residues that form four disulfide bonds. Humans 
possess a single copy of the gene for the hormone (HAMP), while mice 
have a tandem duplication of the gene sequence.  
From the evolutionary point of view, there is a high conservation of the 
gene sequence, from fish to humans.  
The role of hepcidin in the innate immune response is consistent with its 
regulation by inflammatory cytokines such as interleukin (IL) - 6, IL - 1α, IL - 
1β.  
In addition to its anti-inflammatory activity, hepcidin plays a key role in iron 
homeostasis, specifically in the control of its absorption.  
The essential role of hepcidin in the context of iron metabolism has been 
established by the study of mouse models deficient for the peptide. The 
hepcidin KO mice showed a huge iron overload, with a substantial ion 
deposition in liver tissue, pancreas and splanchnic macrophages. These 
effects have led to the conclusion that hepcidin was directly involved in iron 
absorption in the gut and control of ion release by macrophages. [1] (Figure 
1.4) 
 
 
 
 
 
 
 
 
 
 
 
 12 
 
Figure 1.4 : A Model of Homeostatic Regulation of Iron by Hepcidin 
 
Source: Nemeth E., Ganz T. : “regulation of iron metabolism by hepcidin”  Annual Reviews 
Nutritional 2006 
 
Hepcidin has a region to the N terminal, which consists of 5 amino acids 
that has high affinity for FERROPORTIN: their bond causes the 
internalisation and degradation of the latter, thus ensuring a brake in the 
export of iron absorbed by the basal membrane of the enterocyte to the 
blood stream. [2] (Figure 1.5)  
 
 
 
 
 
 
 
 
 
 13 
 
Figure 1.5 : the Action of Hepcidin on Ferroportin 
 
Source: Andrews NC. “Forging a field: the golden age of iron biology.” Blood. 2008 Jul 15; 
112(2):219-30. 
 
It is well established that hepcidin reduces the amount of circulating iron, 
preventing its escape from the cells (mainly enterocytes and macrophages) 
and its entry into the bloodstream by the enterocyte; on the contrary its 
absence causes an increase of iron in the circulation due to the intestinal 
absorption and its release by macrophages. 
 
1.6   The Ferroportin 
Ferroportin is the sole iron exporter so far known in vertebrates. Studies in 
zebrafish and mice have shown that the complete loss of the exporter 
during embryonic development is lethal due to the inability of the ion 
transport across the placenta from the mother to the embryo.  
The presence of ferroportin was detected in all tissues that have a greater 
influx of iron, such as duodenal enterocytes, macrophages and 
hepatocytes. Studies on mice with a selective silencing of the gene, which 
makes ferroportin expressed on the interface foetus - mother, but is inactive 
in other tissues, they observed the early development of iron depletion in 
the new offspring caused by the inability to export the iron from the gut into 
the bloodstream. [1]  
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Ferroportin (FPN, FPN1 or SLC40) is an exporter having 12 
transmembrane domains, with both C and N terminals placed in the 
cytosolic side; it is present on the basolateral membrane of enterocytes, on 
the membranes of macrophages and non-polarized cells (red blood cells). It 
exports the ferrous ion (Fe2+), which must be oxidized to the ferric state by 
a ferroxidase, also needed to stabilize the ferroportin at the level of the 
membranes, before the ion exported binds to transferrin.  
 
1.6.1 Ferroportin and Erythropoiesis 
An adequate intake of iron is important to have adequate erythropoiesis, it 
is known that about 70% of the iron in the body is included in the heme 
group. On the other hand, must be very careful that the iron does not 
accumulate in the erythroblasts during the process of maturation, causing 
cellular toxicity resulting in apoptosis (in this case, haemolysis); for this 
reason it is necessary that the cells of the erythropoietic lineage are 
equipped with an iron exporter such as FPN1. The discovery of FPN1 on 
the membrane of erythroblasts is surprising because it was thought that 
these cells did not need an iron exporter since it was assumed that the 
cellular ion leakage happen only during the process of degradation by 
macrophages.  
Nevertheless, it seems that the expression of FPN1 on red blood cells 
(RBCs) is kept constant throughout the process of cellular maturation, even 
by subjecting the cells to iron chelation treatments or saturation; this leads 
to suppose that on RBCs is present, in addition to FPN1, another isoform 
that is not IRE dependent.  
Currently it is possible to affirm that there are two isoforms of ferroportin: 
the IRE dependent: FPN1A and non - IRE: FPN1B.  
It has been recently demonstrated by Cianetti and Zhang that both 
transcripts are expressed mainly during the intermediate step of 
erythropoietic differentiation in vitro (days 4-11) when we have 
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polychromatic erythroblasts in cell culture; at this stage there is an 
increased expression of the transferrin receptor, solely responsible for the 
entry of iron in erythroblasts. The FPN1B increases its expression when 
cells need iron to accumulate in them, it is thought that the cells during 
erythroid differentiation transcribe a constant level of FPN1B that remains 
insensitive to high levels of iron present in the erythroblasts.  
The FPN1A instead is transcribed at high levels on day 0 of erythropoiesis, 
when we still have erythroid precursors in cell culture and at the final step 
of maturation (day 14) when we get mature RBCs, suggesting a possible 
role in these stages of differentiation.  
The lack of production of FPN1A at the intermediate step of erythroid 
maturation can be attributed to the fact that, at this level of differentiation, 
the cells are in need of a lot of iron, therefore it would be deleterious having 
an exporter that is expressed in function of martial concentrations; for this 
reason the cells of the erythroid lineage express the isoform 1B in a 
constant manner throughout the differentiation, since the protein has the 
role to protect the cellular toxicity caused by extremely high concentrations 
of iron. [3] (Figure 1.6)  
The two isoforms of FPN1 arouse much interest, a recent study has 
suggested that the functionality of the exporter, located on the erythrocytes 
membrane, is to ensure a partial suppression of erythropoiesis if the non 
erythropoietic tissues risk the development of iron depletion. This explains 
why situations characterized by iron deficiency (anaemia) are the main 
conditions that herald the manifestation of iron depletion in mammals. [4]  
The discovery of FPN1B may have important physiological implications. 
Since the FPN1 is locked by hepcidin, the exporter in the erythroblasts is 
functional only when there is a situation of iron depletion (in which hepcidin 
is poorly expressed). The expression of FPN1B in the erythroblasts can 
represent a development of a mechanism to prevent an erroneous 
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distribution of iron. In conditions of wide availability of the ion at the 
systemic level, the down-regulation of FPN1 ensures the retention of the 
iron inside the erythroblasts, which will require large amounts to ensure the 
production of heme and, consequently, to allow erythropoiesis. In contrast, 
in conditions of iron deficiency, erythroblasts allow other tissues (such as 
heart and brain) to have priority regarding the iron uptake, preventing these 
organs to be iron deficient. Whereas erythroblasts have an efficient 
mechanism for the recovery of iron (the transferrin receptor is highly 
expressed on the surface of these cells) and that only 1% of the erythrocyte 
population is recycled daily, is decidedly better for the body to decrease the 
erythropoietic activity during a condition of iron depletion and thus avoid the 
risk of shortage of the ion in the vital organs. The connection between the 
expression of hepcidin and ferroportin at the level of erythroblasts may 
explain why anaemia is commonly the first symptom of a systemic iron 
deficiency. [4][5] 
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Figure 1.6 : FPN1 Expression During Erythropoiesis 
Source: Cianetti L. Gabbianelli M. Sposi N.M.:” Ferroportin and Erythroid Cells: an Update”. 
Advance in Hematology, 2010 
 
1.6.2   Transcriptional Regulation of FPN by non-Iron Molecules 
- Heme 
Recent studies conducted by Marro, lead to the conclusion that, in the 
macrophages, there is another mechanism of regulation of FPN1 non-iron 
related. They discovered that an increasing of haemoglobin caused an 
increase of FPN1 expression, with the possible conclusion that the 
haemoglobin can directly regulate the transcription of the iron exporter 
through a system involving the Btb And Cnc Homology 1 (Bach1), Nuclear 
Factor Erythroid 2-like (NFR2) and the Maf Recognition Elements 
(MAREs). (Figure 1.7)  
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Heme controls the transcription of the iron exporter FPN1 involving Bach1 
activity, Nrf2 nuclear accumulation and a highly conserved MARE/ARE 
enhancer element located at the FPN1 promoter. This finding suggests that 
iron recycling from heme involves a single transcription control mechanism 
that regulates heme catabolism, iron storage and detoxification, as well as 
iron export in a coordinated manner. [6] 
In the macrophage cell, heme and/or haemoglobin induced FPN1 
transcription may thus enhance systemic iron availability to sustain 
erythropoiesis under conditions when intact erythrocytes are limiting. 
 
Figure 1.7: How Heme/Haemoglobin Can Regulate the FPN1 
Transcription 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Marro S., Chiabrando D., Messana E., Stolte J., Turco E., Tolosano E., 
Muckenthaler MU.: “Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 
and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter”. Haematologica, 
2010 
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- HIF1α 
One of the major physiological cues for increased iron absorption is 
hypoxia/anaemia. Increased erythropoiesis leads to increased iron 
absorption and elevated levels of FPN mRNA. McKie et al.'s discovery of 
FPN was based on increased expression of its mRNA in the duodenum of 
the hypotransferrinemic mouse [7]. This mouse is severely anaemic and 
shows increased hypoxic response. Hypoxia leads to wide changes in 
transcription including genes involved in iron [8] The Fpn promoter contains 
HIF-Responsive Elements (HRE) and an Fpn reporter construct responded 
to low oxygen (studies confirmed by ChIP on the Fpn promoter). 
 
1.6.3 Post – Transcriptional and Post - Translational Regulation of 
FPN 
The FPN mRNA was identified by its ability to bind to Iron Regulatory 
Protein 1 (IRP1). Subsequent studies showed that translation of FPN or 
FPN reporter constructs containing the IRE was inhibited by low iron and 
increased by high iron. The importance of the 5′-IRE was underscored by 
the discovery of a mouse that had a mutation that deleted the IRE. A 
radiation-induced mutation in mice was identified, resulting in a 58bp micro 
deletion in the Fpn promoter region [8]. This deletion altered the 
transcription start site and eliminated the 5′-IRE, resulting in increased 
duodenal and hepatic Fpn protein levels during early postnatal 
development. It is unclear why Fpn mRNA levels were decreased. Iron 
overload in adult mice was attributed to increased Fpn protein expression 
due to the absence of the 5′-IRE. Age-related anaemia was ascribed to a 
loss of splenic stromal cells. The reason for this loss was not determined. 
Analysis of mRNA transcripts in mouse duodenum and erythroblasts and in 
human erythroblasts identified a FPN transcript which lacked the 5′-IRE, 
termed FPN1B. The translation of FPN1B is insensitive to iron. The reading 
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frame of the protein, however, is identical to that of the IRE-containing 
transcript and the protein can transport iron and respond to hepcidin. 
FPN1B accounted for 25% of total FPN mRNA in duodenum but constituted 
a much higher percent of FPN transcripts in erythroblasts [5]. It was 
suggested that the FPN1B in the intestine might still export iron even under 
conditions of iron deficiency. In the developing erythroblast, iron-insensitive 
translation of FPN might make erythropoiesis sensitive to hepcidin levels 
and thus sensitive to systemic iron deficiency [4]. 
 
1.6.4 Post - Translational Regulation of FPN 
The importance of FPN1 is put in further evidence when it is related to 
hepcidin, because the iron exporter is also the ligand of the hepatic 
hormone. Hepcidin binds to ferroportin and promotes its internalization 
through phosphorylation of amino acids placed at the level of the 
intracellular loop of the exporter. The complex FPN1 - hepcidin is so 
internalized and promoting the ubiquitination and lysosomal degradation of 
both proteins. [9][10](Figure 1.8)  
The roles of hepcidin and FPN were cemented by the striking observation 
that mice with a targeted deletion in Hamp were massively iron-loaded [11]. 
In contrast, overexpression of hepcidin in mice led to severe iron deficiency 
[12]. A study in humans showed that overexpression of hepcidin, as seen in 
a severe example of the Anaemia of Chronic Inflammation, resulted in 
hypoferremia [13]. In contrast, the recessive iron overload diseases were 
due to decreased levels of hepcidin [14]. These studies showed that 
hepcidin affected entry of iron into blood. How this occurred was elucidated 
by Nemeth et al., who demonstrated that hepcidin bound to and induced 
the internalization of FPN expressed in cultured cells [2]. The observation 
that FPN levels were affected by hepcidin explained both recessive iron 
overload disorders resulting from decreased hepcidin and iron deficiency 
disorders resulting from increased levels of hepcidin. The relationship 
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between hepcidin and intestinal FPN, however, remains cloudy. Chronically 
high levels of hepcidin lead to loss of intestinal FPN, but studies have 
shown that acute changes in hepcidin have a modest effect on intestinal 
FPN levels. At the same time, however, acute changes in hepcidin have a 
significant effect on FPN levels in splenic macrophages [15][16]. Analogous 
results were reported in intestine- like cell lines; acute hepcidin exposure 
had little effect on FPN levels but did affect iron transport activity. The 
mechanism of hepcidin-mediated FPN internalization in macrophages and 
many other cultured cell types has been described. The binding site for 
hepcidin has been identified as an extracellular loop in FPN in which the 
residue Cysteine 326 is absolutely required for hepcidin binding [17]. 
Mutation of C326 leads to hepcidin- resistant hemochromatosis in patients. 
The importance of FPN in iron homeostasis is supported by the fact that it 
is regulated at many different levels. Many of aspects of that regulation 
remain to be clarified. The transcriptional regulation of FPN in response to 
iron or to inflammation requires identification of the critical transcriptional 
activators or repressors. What also requires clarity is the reason for the cell 
type variation in transcriptional regulation of FPN and in the subcellular 
location of FPN. Why do different FPN mutants show differences in 
subcellular localization in different cell types?  
This lead us to further investigate about the role of this protein in the big 
puzzle of the iron metabolism. 
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Figure 1.8 : Internalization and Degradation of the Hepcidin – 
Ferroportin Complex  
 
Source: Mackenzie E.L., Iwasaki K., Tsuji Y. “Intracellular Iron Transport and Storage: From 
Molecular Mechanisms to Health Implications” Antioxidant and Redox Signaling; Volume 10, 
Number 6, 2008 
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CHAPTER 2: THE THALASSEMIC SYNDROMES 
The thalassemias are a heterogeneous group of Mendelian disorders, 
which are characterized by a lack or a decreased synthesis of α or β chain 
of haemoglobin A (α2β2). [18] On the basis of the chain missing it is 
possible to distinguish between α-thalassemia and β-thalassemia. The 
thalassemias are one of the most common genetic disorders in the world 
with an estimated number of bearers more than 270 million and more than 
350,000 people affected; they are particularly affected the populations of 
the Mediterranean, Africa, India and the Orient. In Italy are prevalent forms 
of β-thalassemia, which is endemic mainly in Sicily and Sardinia. [19] 
 
2.1   The β - Thalassemia 
The β-thalassemia is characterized by the deficient synthesis of β chains, 
while the synthesis of α chains remains unchanged. The altered production 
of β chains is due to the presence of point mutations or small deletions at 
the level of the β globin cluster on chromosome 11. Such mutations may 
cause a failure or reduced synthesis of β chains; we speak respectively of 
β0 and β+ thalassemias. [18] [20]  
Genotypically the β thalassemias are very heterogeneous; up to date more 
than 200 mutations in the beta globin gene causing partial deficiency (α+ or 
β++) or total (β0) of synthesis of beta globin chain are known. Defects in 
transcription, maturation and translation of messenger RNA have been 
identified. Defects by deletion of the gene of beta globin are rare and 
limited to sporadic families.  
Here is a list of the major flaws of expression of the beta globin gene:  
- Defects in transcription: in most cases, they are point mutations within 
the promoter region, at the 5' end of the gene. Simple nucleotide 
substitutions are able to reduce of 30-50% the transcription of the beta 
gene and mutations are defined β+ as there is a residual activity of 
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transcription. The hematologic phenotype is very mild, sometimes 
completely silent. Small deletions at the 5' end of the gene responsible for 
complete inactivation of the transcription process have been detected in 
few cases. In this case, the defects are defined β0.  
- Defects in the maturation of messenger RNA:  
1) Alterations of splicing: about half of the thalassemia mutations fall into this 
group. It is required, for a proper splicing, that at the junction between 
introns and exons, there is the presence of 2 pairs of dinucleotides 
unchanged: GT at the 5' and AG at the 3' of the intron. Intronic mutations 
can delete a normal site of splicing by destroying one of the two nucleotides 
unchanged. In Italy the most frequent mutations of this type are IVSI - 1 
G/A and IVSII-1 G/A both β0. Mutations that reduce the efficiency of splicing 
by altering its consensus sequence are also known. Among these, the most 
frequent in Italy is the IVSI - 6 T/C, that leaves a residual activity and it is 
defined β+ mutation. In this context, other mutations in β+ (with low residual 
activity) are those that create another splice site by producing the GT or AG 
nucleotides in a site that competes with the normal one. The most common 
mutation in Italy are IVSI – 110 and IVSII - 745.  
2) Mutations in the cutting site and at the polyadenylation site of pre-RNA: in 
the process of maturation of the primary transcript of the RNA messenger, 
or pre-RNA, it is important to cut the terminal part in correspondence with 
the sequence AATAAA and the addition of a tail of residues of adenylic acid 
(poly-A) which increase the speed of translation and the stability of the 
messenger. If the sequence AATAAA is changed, the two processes occur 
much more downstream and the mRNA produced is longer and unstable. 
These mutations lead to defects of type β+.  
- Defects of translation of RNA messenger:  
1) Mutations in the start codon of translation: all give rise to defects of type β0, 
and are sporadic mutations. 
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2) Non-sense mutations: they consist in the substitution of a purine base in 
the codon of coding RNA, which gives rise to the formation of a stop codon 
resulting in an arrest of translation of the messenger. The most common 
mutation is the β039 (or cod39).  
3) Frame shift mutations: it comes to insertions or deletions in the DNA of one 
or more nucleotides that cause a shift of the reading frame of the RNA 
messenger and hence a more or less early arrest of translation. If the shift 
starts in a codon away from the stop codon, the synthetized chain will have 
an amino acid sequence altered and will be shorter than normal. If the 
mutation is located in a region closer to the end of the translation, this will 
continue until it comes across a new stop codon producing a globin chain 
stretched. In any case, there is a lack in normal globin chains, thus 
constituting type defects β0.  
- Mutations that cause instability of the beta globin chain: they are 
nonsense mutations, frame shift or deletions within the exon 3. They 
generate elongated chains (rarely truncate) highly unstable that precipitate 
before forming tetramers with the alpha chains. These mutations are 
considered dominant in that, even if in heterozygosis, they cause a relevant 
clinical condition (thalassemia intermedia). [21] 
    
The thalassemias associated to this genotype β0/β0 or β0/β+ are defined 
Major, since they present a clinical condition much more severe than the 
one more heterogeneous and milder observed in thalassemia Intermedia.  
The description and characterization of the various forms of thalassemia, 
however, is based more on the clinical severity than the type of mutation 
present. The phenotypic expression of β-thalassemia varies from a clinical 
condition almost normal with a minimally imbalanced globin (thalassemia 
minor) to situations of severe anaemia associated with a genotype β0/β0 or 
β0/β+ (thalassemia major).  
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The individuals homozygous β0 as well as the double heterozygous β0/β+ 
and many homozygous β+ develop a clinical picture of thalassemia major 
which is manifested in early childhood with severe transfusion-dependent 
anaemia. With the term "thalassemia intermedia" are defined cases instead 
genotypically heterogeneous, characterized by a clinical condition more 
moderate, late-onset and with the absence of transfusion requirements at 
least for long periods. [22]  
 
2.2 Thalassemia Major  
The clinical manifestations of thalassemia major (TM) typically occur in the 
first year of life.  
The genotype is characterized by the lack of presence or the total absence 
of beta globin chains, while the production of alpha chains remains 
unchanged. In patients with thalassemia, erythropoiesis is severely altered 
because the red blood cells will never come to fruition due to the 
accumulation of alpha globin chains, which are complexed to heme forming 
the Heinz bodies. From the maturational point of view, we are at the 
intermediate step of erythrocyte differentiation (day 7), where there is an 
abundance of polychromatic erythroblasts that will be degraded by a 
phenomenon called intramedullary haemolysis: the Heinz bodies precipitate 
at the membrane level of these erythroblasts devoid of haemoglobin and 
cause serious alterations incompatible with the survival of the cell, which is 
then eliminated.  
Phenotypically TM subjects have chronic severe anaemia, accompanied by 
tissue hypoxia, which can be cured by transfusion only, so much so that 
thalassemia major is also described as transfusion dependent.  
The continuous transfusions are used to compensate for the lack of red 
blood cells in the periphery and erythropoiesis in these patients is almost 
absent. [23] [24] (Figure 2.1)  
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The problem of anaemia, however, is much more complex, it is not solved 
with the transfusions. In situations of anaemia is observed the stimulation of 
the production of erythropoietin (EPO) in an attempt to increase 
erythropoiesis in the bone marrow (up to 25-30 times the normal levels) 
without succeed. In fact, it is impossible to restore a physiological situation, 
as there are anomalies at the globin chain, causing the absence or a 
decreased production of haemoglobin in red blood cells, which makes it 
impossible to hold optimal erythropoiesis.  
Unfortunately, the strategy of transfusion may be a solution for chronic 
anaemia, but it leads to the development of an additional problem: the iron 
overload.  
Echoing what has been said in the first chapter, it was observed that 
hepcidin is silenced by hypoxia and ineffective erythropoiesis, this inhibition 
of hepatic hormone is found in those thalassemia intermedia conditions; so 
there is an iron overload due to the increase in intestinal absorption and 
ineffective erythropoiesis. Regarding the thalassemia major, the levels of 
hepcidin are not affected by the contribution of iron given from transfusions 
as this iron is exogenous.  
This overload leads to a total transferrin saturation and the appearance of 
free non-transferrin-bound iron (NTBI), which accumulates in the tissues of 
the heart and endocrine organs causing severe toxicity if not treated 
pharmacologically. [24] 
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Figure 2.1: Erythropoiesis and Thalassemia 
 
Source: Yelena Ginzburg, Stefano Rivella: “β-thalassemia: a model for elucidating the 
dynamic regulation of ineffective erythropoiesis and iron metabolism”. Blood, 2011. 
 
2.2.1 β – Thalassemia Therapy 
The mainstay of therapy in patients with thalassemia treated with blood 
transfusion is therefore represented by the iron chelation therapy with 
deferoxamine or with the newer oral chelators: deferiprone and deferasirox. 
The term chelation refers to a chemical reaction in which usually a metal 
atom, behaving as a Lewis acid, binds a reagent called chelator through 
more than a coordinative bond. The structure of the resulting compound is 
a particular complex very stable (Figure 2.2). It shows that the central atom 
is surrounded by a chelating pincer, as if caught between the claws of a 
crab (hence the term chelation). In the biological field, haemoglobin binds 
iron through the chelation. In medicine chelation is exploited in the 
chelation therapy for the treatment of some forms of intoxication due to the 
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accumulation of metals in the body: once chelated, the metal loses its 
characteristics (and therefore it loses its toxicity) and then be eliminated 
tied together the chelating through the urinary tract. 
 
Figure 2.2 : Example of a Metal Chelation 
 
The most common chelating agents in the treatment of thalassemia are: 
desferoxamine (trade name of the drug: Desferal) which is administered 
intravenously, or the oral chelators such as deferiprone and deferasirox.  
Deferoxamine (DFO) forms complexes with Fe3+. The affinity of DFO for 
divalent ions such as Fe2+ is substantially smaller. The chelation occurs 
with molar ratio 1: 1, (i.e.1 g of DFO can theoretically bind 85 mg of trivalent 
iron). Thanks to its chelating properties, DFO can bind free iron both in 
plasma and cells, forming the complex ferrioxamine (FO). The urinary 
excretion of FO is derived mainly from the turnover of plasmatic iron, while 
the iron present in the feces mainly reflects the intrahepatic chelation. The 
iron can be chelated by ferritin and by hemosiderin, but is relatively low at 
clinically relevant concentrations of DFO. The DFO does not mobilize the 
iron content in transferrin, hemoglobin or other substances containing the 
heme group. 
Other alternative therapies for the β - thalassemia include the bone marrow 
transplantation from HLA-identical donor family that made possible to 
achieve a cure in 80% of cases, but only for subject at the paediatric age. 
[21] Although transplantation may allow the resolution of the disease, it may 
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not be successful and may lead to complications (GvHD, abnormal growth 
or neurological complications). To date, the transplant is considered 
appropriate only for patients with an HLA-identical donor, hence, for 30-
40% of all β-thalassemia patients. [25] 
New experimental therapies include gene therapy and induction of fetal 
hemoglobin (HbF).  
The autologous transplant of hematopoietic stem cells corrected by vectors 
containing the β-globin gene is the basis of gene therapy of β-thalassemia. 
In recent years there have been numerous studies on in vitro cultures of 
CD34+ stem cells derived from patients with thalassemia major treated with 
lentiviral vectors and on mouse models of β-thalassemia; all gave 
promising results thus provide a solid rationale for clinical application. [26] 
Despite these early observations, many studies are still needed to make it 
possible to consider gene therapy as a definitive solution of β-thalassemia. 
 
2.3   Thalassemia Intermedia 
The clinical phenotype of thalassemia intermedia (TI) is extremely 
heterogeneous and it is intermediate between thalassemia major and 
minor, although there are many features in common between the three 
conditions. Some patients are completely asymptomatic until adult life, and 
have only a moderate anaemia; these patients require only occasional 
transfusions as needed. Other patients have a severe anaemia that occurs 
between 2 and 6 years, and although they are able to survive without a 
regular transfusion regimen, they present alteration in growth and 
development. [26] [27]  
Three factors are responsible for the clinical sequelae of TI: ineffective 
erythropoiesis, chronic anaemia and iron overload. Unlike TM, thalassemia 
intermedia has an accumulation of iron due to intestinal absorption. [28] Do 
not forget that the severity of the clinical condition mainly depends on the 
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underlying molecular defects that cause ineffective erythropoiesis and iron 
overload. 
 
2.3.1  The Ineffective Erythropoiesis 
Erythropoiesis is a physiological process by which, in the bone marrow, 
mature erythrocytes are generated starting from their CD34+ erythroid 
precursors. Erythropoietin (EPO) is the major regulator of this process and 
its release by the kidney is determined by situations such as hypoxia and 
iron depletion. Here it is possible to find a first correlation between 
erythropoiesis and hepcidin: the synthesis of red blood cells occurs if the 
hepatic hormone is not working.  
In pathological conditions such as thalassemias it is possible to see the 
phenomenon of ineffective erythropoiesis. (Figure 2.3)  
Ineffective erythropoiesis in β thalassemia is characterized by the 
expansion, poor differentiation and premature death of erythroid precursor 
cells through a process mediated by factors involved in the cell cycle, iron 
intake and heme synthesis. [29]  
In TM there is a supply of red blood cells by blood transfusions that cause 
an almost complete silencing of the erythropoietic apparatus of the patient, 
for this reason thalassemia major is not a good model for the study of the 
ineffective erythropoiesis. It is instead thalassemia intermedia, being 
transfusion independent, allows a better study of the phenomenon. 
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Figure 2.3 : Ineffective and Normal Erythropoiesis  
 
Source: Yelena Ginzburg, Stefano Rivella: “β-thalassemia: a model for elucidating the 
dynamic regulation of ineffective erythropoiesis and iron metabolism”. Blood, 2011. 
 
The erythropoietic apparatus of TI is affected by alterations in the 
production of beta globin chains; this leads to an incomplete maturation of 
erythrocytes: most of them undergoes an intramedullary hemolysis, while 
the red blood cells that are able to reach the bloodstream, are eliminated 
due to the deposition of Heinz bodies at the level of the membranes that 
alter their structure. (Figure 2.4)  
Intramedullary and peripheral haemolysis generate a state of hypoxia that 
ensures the production of erythropoietin, which will stimulate erythropoiesis 
but, as it has been seen, is incomplete. This establishes a vicious circle 
also characterized by a continuous iron overload. The iron overload in TI, 
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unlike the TM, is not due to transfusions, but to the continuous intestinal 
absorption and to the continued destruction of the erythrocytes by the 
reticuloendothelial apparatus (RE) that releases iron into the bloodstream; 
iron that was supposed to compose the heme group.  
Iron overload in thalassemia is due to the fact that, at the molecular level, 
there is an incorrect regulation of hepcidin. 
 
Figure 2.4 : The Iron Increase in to Erythroid Progenitors Causes 
Damage and Apoptosis 
 
Source: Yelena Ginzburg, Stefano Rivella: “β-thalassemia: a model for elucidating the 
dynamic regulation of ineffective erythropoiesis and iron metabolism”. Blood, 2011. 
 
2.4  Hepcidin / Ferroportin and Thalassemic Syndromes 
This chapter has highlighted the procedure of transfusion TM in order to 
cope with chronic anemia; transfusions induce an increase in heminic iron 
circulating in the patient. If hepcidin was regulated primarily by iron, it 
should be observed an increase in its expression; well, in the sera of 
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patients affected by beta thalassemia very low levels of hepcidin have been 
reported compared to healthy controls. [30] This leads to the conclusion 
that in the thalassemias hepcidin is not expressed due to altered 
regulations upstream of the gene.  
Unluckily there is very few information about the expression of Ferroportin 
into the erythroblast cells in healthy and thalassemic subject. For this 
reason is important to further investigate in order to see how this protein 
involved in the iron metabolism is expressed and regulated in the 
thalassemia syndromes. 
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CHAPTER 3: THE ERYTHROID DIFFERENTIATION 
3.1.   The Haemopoiesis 
The blood cells can be classified into two main categories: lymphoid cells 
(B cells, T and natural killer) and myeloid cells (granulocytes, monocytes, 
erythrocytes and megakaryocytes); since they all have a limited life 
expectancy (several hours for granulocytes, few weeks for erythrocytes and 
few years for the memory T cells), they must be continually renewed or 
replaced. [31] [32]  
The mature cells all originate from a hematopoietic multipotent stem cell 
(HSC); from this common precursor derive the pluripotent stem cells 
lymphoid and myeloid; from the latter (CFU-GEMM) arise at least three 
types of progenitor cells commissioned, that are oriented towards the 
differentiation into erythroid lineage, megakaryocytic, eosinophilic or 
granulocytic - macrophage.  From the different commissioned stem cells, 
take origin the precursors, morphologically recognizable, of differentiated 
cell lines: proerythroblasts, myeloblasts, megakaryoblasts, monoblasts and 
eosinophiloblasts. From these derives the mature progeny.  
Hematopoiesis is therefore a highly regulated process consisting of several 
stages:  
i) Commitment to a specific chain differentiation,  
ii) Proliferation and differentiation of progenitors,  
iii) Maturation of precursors  
In adult life, the bone marrow is the only site of production of the HSC, 
which constitute a very small percentage, estimated to be between 0.05% 
and 0.5% of all bone marrow cells.  
Multipotent stem cells HSC can self-renew or differentiate into progenitors 
commissioned, which lose their ability to self-renewal and give rise to 
mature cells having a particular function.  
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The choice between the two possible fates (self-renewal or commitment), is 
highly regulated by both intrinsic signals (transcription factors, signal 
transduction molecules, factors that regulate the cell cycle) and the external 
microenvironment. 
 
Figure 3.1 :  The Haematopoiesis  
 
Source: eBioscience 2012 
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The bone marrow microenvironment plays a critical role in the regulation of 
haematopoiesis; it includes stromal cells, the extracellular matrix molecules 
and soluble cytokines that act as growth factors and differentiation by 
binding to specific receptors expressed on the surface of hematopoietic 
progenitors.  
The various growth factors may act at different stages of hematopoietic; 
these factors are known and well characterized; they are essential for the 
recruitment of progenitor stem cells and guarantee their entry into the cell 
cycle, which is normally at G0 phase.  
Among the factors that act at the level of primitive progenitors, has 
particularly importance the factor SCF (stem cell factor or c-kit ligand) 
produced by stromal cells and essential for the self-renewal of pluripotent 
stem cell. [33]  
The commitment to a specific lineage of differentiation is determined by the 
nature and concentration of the factors acting on the progenitor cells.  
While precursors and mature cells can be recognized morphologically, 
stem cells and commissioned progenitors can be only identified through in 
vitro functional assays or with immunophenotypic analysis.  
The functional assays are based on the ability of the hematopoietic 
progenitor cells to generate colonies of mature cells in appropriate culture 
conditions and with the appropriate growth factors.  
From the immunophenotypic point of view, stem cells are characterized by 
the presence of surface antigens: CD34 and AC133. [34]  
The CD34+ cell fraction is heterogeneous, including both primitive cells 
(stem cells HSC) and commissioned cells (progenitors); the concomitant 
expression of CD34 and immunological markers associated to a specific 
lineage, such as CD38 and HLA-DR, however, allows distinguishing the 
population into subpopulations of progenitors more or less primitive.  
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The CD34+ cells can also be found in the umbilical cord blood and 
peripheral blood. Under physiological conditions, 1-3% of the mononuclear 
fraction of the bone marrow express the CD34 antigen, compared with 0.1-
0.2% of peripheral blood and 0.8-1.2% of umbilical cord blood. 
 
3.2   The Erythropoiesis  
The process of formation of mature erythrocytes from the circulating 
hematopoietic stem cell (HSC) is called erythropoiesis. It consists of 
several stages: HSC commitment in a erythroid way, proliferation and 
differentiation of progenitors (BFU-E and CFU-E) and maturation of 
erythroid precursors or erythroblasts.  
Erythropoiesis is regulated by several cytokines and growth factors, which 
by binding to specific receptors located on the membrane of erythroid 
progenitors or precursors, induce the activation of transcription factors; 
these by binding to specific DNA sequences, allow the expression of genes 
necessary for proliferation, differentiation and maturation.  
Going through the various stages of erythropoiesis cells lose their ability to 
differentiate into other cell types (lymphocytes, monocytes, etc...) and 
become more oriented in erythroid sense.  
Before the formation of polychromatic erythroblasts, the number of cells in 
each stage is higher than the previous one; this is due to the intense 
activity of cell division. Besides this step, the erythroid cells do not divide 
but they undergo a process of maturation that leads to the formation of 
erythrocytes, cell characterized by the absence of nucleus and organelles, 
with a haemoglobin content of more than 30% of the total volume. [35] 
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Figure 3.2 :  The Erythroid Differentiation 
 
Source: Elliott S., Sinclair AM. : “The effect of erythropoietin on normal and neoplastic cells.” 
Biologics, 2012 
 
The erythroid precursors are morphologically recognizable as the ancestors 
of mononuclear cells are identifiable only on the basis of functional tests.  
 
The BFU-E (burst-forming unit erythroid) and CFU-E (colony forming unit 
erythroid) constitute the first commissioned elements capable of forming 
colonies when stimulated with appropriate growth factors and, in particular, 
with erythropoietin.  
The BFU-E after 14-16 days of culture in semisolid medium give rise to 
macro colonies (burst) of polychromatic orthochromatic erythroblasts 
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containing haemoglobin. The BFU-E cells are mostly quiescent (only 10-
20% is in the cycle) and are also present in peripheral blood (10-20 BFU-E 
per 105 of total cells). They express on the cell surface antigens such as 
CD34 and HLA class 2; only the late BFU-E also have a small amount of 
receptors for erythropoietin.  
The CFU-E progenitors are considered to be more mature than the BFU-E, 
for this reason, when placed in culture, it only takes 5-6 days to form 
erythroid colonies. The CFU-E have an intense proliferative activity: most of 
them are located in the S phase of the cell cycle; these cells have lost the 
ability to self-renew and are not present in the periphery. The CFU-E no 
longer express CD34 on their surface nor HLA 2, while they acquire surface 
proteins specific to the erythroid lineage such as glycophorin A and antigen 
of the Rh system, in addition to erythropoietin receptors: these reach a 
maximum amount of 1.1x103 per cell. [35]  
The population of erythroid precursors is composed by pro-erythroblasts, 
basophilic erythroblast, polychromatic erythroblast, orthochromatic 
erythroblast, reticulocyte and erythrocyte finally. 
 
Figure 3.3 : The Erythroid Precursors 
 
Source: Immunopaedia.org. Website  
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In the process of red blood cell maturation there is a progressive decrease 
in cell size (20-25µm for the pro-erythroblast, 7µm for the erythrocyte) and 
in the ability of protein synthesis.  
At the stage of reticulocyte there is the complete ejection of the nucleus 
and the subsequent degradation of cytoplasmic organelles; this appears to 
be mediated at least in part by the 15-lipoxygenase, which would enhance 
the enzymatic oxidation of the phospholipids and the permeabilization of 
the membrane organelles.  
During the final stages of erythropoiesis there is then a gradual increase in 
the expression of anti-apoptotic gene Bcl-XL, which allows cell survival.  
With the elimination of mitochondria and lysosomes, the erythrocyte can be 
considered mature. The main function of red blood cell is to carry oxygen 
from the lungs to peripheral tissues and carbon dioxide from the tissues to 
the lungs by using haemoglobin. The erythrocyte is able to perform these 
functions thanks to its digestive and metabolic enzyme and the structure of 
its membrane.  
With the disappearance of ribosomes, the decline of the red blood cell 
begins and ends with the complete elimination in the spleen. [35] [36] 
 
3.2.1 Growth Factors Regulating the Erythropoiesis 
Proliferation, maturation and differentiation of erythroid progenitors are 
regulated by the interaction of several hematopoietic growth factors (SCF, 
EPO, TPO, IL-3, IL-6, GM-CSF, G-CSF) with specific membrane receptors 
and with the consequent activation of the appropriate signal transduction 
pathways. 
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Figure 3.4 :  Growth Factors Regulating Erythropoiesis 
 
Source:   Stamatoyannopoulos G., “The molecular basis of blood diseases”, 2001 
 
Growth factors can be classified in several ways:  
 depending on the cell type on which they act (primitive progenitors or 
already commissioned in a specific differentiation pattern)  
 according to the type of receptor to which they bind (with intrinsic tyrosine 
kinase activity or not)  
 depending on the mode of presentation to the target cells (such as soluble 
factors, molecules requiring a direct cell-to-cell or as part of the bone 
marrow microenvironment). [37]  
The various hematopoietic cytokines have a common tertiary base 
structure; the specificity of binding to the receptor is guaranteed by the 
presence of a particular surface set of amino acid residues that are different 
from cytokine to cytokine.  
Even hematopoietic receptors have a common basic structure; their 
segment contains a cytoplasmic domain with tyrosine kinase activity, which, 
however, is inactive in the absence of phosphorylation. The binding of the 
receptor with the growth factor induces the activation of this kinase activity 
through a mechanism based on dimerization.  
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Cytokines are dimeric and allow the interaction of two receptor subunits; 
the juxtaposition of the two catalytic domains promotes the mutual 
activation and phosphorylation (trans-phosphorylation). The tyrosine 
phosphorylated form the binding site for the molecules capable of 
transduce the signal [39].  
The erythropoietic factors are able to activate different signal transduction 
pathways, among which there are p42 MAP kinase/44 (Mitogen Activated 
Protein Kinase), JAK-STAT kinase and PI-3K-AKT axis (phosphoinositide 
3-kinase). In particular, cell proliferation is linked to the simultaneous 
activation of the axis p42 MAPK/44 and JAK-STAT, which induce the 
expression of the mitogen genes c-myb, c-myc and c-sis. Cell survival 
instead requires the activation of PI-3K-Akt axis which allows the 
expression of the genes for erythroid differentiation, and probably of the 
anti-apoptotic gene Bcl-XL. [35] [38] 
 
 Erythropoietin  
Erythropoietin is the primary regulator of erythropoiesis; it acts both at the 
level of primitive progenitors (BFU-E) in combination with other growth 
factors (c-kit ligand, TPO, IL-3), and of late progenitors (CFU-E) allowing 
the final differentiation.  
Erythropoietin is a sialoglycoprotein composed of 165 amino acids and with 
a molecular weight of about 34 kD. In the foetus it is produced mainly in the 
liver, while in the adult the organ responsible for the synthesis of more than 
80% of the circulating hormone is the kidney, in particular, the cells of the 
internal cortical and those adjacent to the proximal convoluted tubules; only 
a minor part (about 10%) is synthesized in the liver. [39]  
The main physiological factor that regulates the production of erythropoietin 
is the supply of oxygen to the tissues, a condition of hypoxia induces an 
increase in serum levels of EPO. The increased production of EPO is 
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mainly due to increased gene transcription: is demonstrated the presence 
of a hypoxia-inducible element at the level of the promoter and at the 
flanking region in 3' end of the gene for EPO, located on chromosome 7. It 
is also possible a regulation at the mRNA level: a protein has been 
identified, (whose levels are increased in hypoxia) which binds to the 
untranslated region 3' (UTR) of EPO mRNA, prolonging its stability.  
Erythropoietin allows the body to face the condition of hypoxia in three 
ways:  
- Stimulates the release of normoblasts in the bone marrow  
- Increases the amount of hemoglobin synthesized by each erythrocyte  
- Stimulates the growth of BFU-E and CFU-E differentiation into mature red 
blood cells.  
The increased number of circulating erythrocytes thus obtained is probably 
not due to an increased cell proliferation, but rather to the survival of a 
higher proportion of erythroid progenitors. It was shown, in an in vitro 
culture systems, that EPO prevents programmed cell death (apoptosis) at 
the level above the CFU-E and erythroblasts stage, expanding thereby 
erythropoiesis. [37] Erythropoietin therefore acts more as a survival factor 
that is not as mitogen.  
According to the model proposed by DeMaria, the presence of EPO allows 
the activation of the transcription factor GATA1 and the subsequent 
expression of the anti-apoptotic gene Bcl-XL. In the absence of EPO there 
is instead the binding of Fas-Ligand to its receptor: this leads to the 
activation of caspases, cleavage of GATA1 and then the cell death by 
apoptosis. [40]  
EPO plays its role by binding to a specific receptor (EPO-R) on the cell 
surface of erythroid precursors; the gene for this receptor is localized on 
chromosome 19p and encodes a protein of about 55kDa. The number of 
receptors per cell varies in relation to the stage of differentiation and 
maturation, being maximum at the CFU-E/erythroblasts stage, as well as in 
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relation to the serum levels of erythropoietin: a decrease of these induces 
an increase in the number of receptors.  
The expression of EPO-R depends mainly on the transcription factor 
GATA1; also are important the binding sites for Sp1 and CACCC 
consensus sequence located in the promoter, in addition to DNase 
hypersensitive sites of the LCR (locus control region) upstream of the 
starting site of transcription. [37] 
 
3.2.2 Transcription Factors Regulating Erythropoiesis 
The differentiation and proliferative potential of progenitors to a different cell 
line (commitment) is regulated by factors that allow the transcription of 
specific genes for that cell lineage; this occurs through binding to the 
consensus sequences present within promoters, enhancers and in the 
DNase 1-hypersensitive sites of the LCR.  
The transcription factors can be divided into two categories: the firsts act at 
the level of pluripotent progenitors determining the erythroid commitment 
(TAL1, LMO2, GATA2), the seconds induce the differentiation and 
maturation of commissioned precursors (NF-E2, EKLF, GATA1). [41] 
 
Figure 3.5 : Transcription Factors Regulating Erythropoiesis 
 
Source : Oncogene, vol. 21, p. 3372, 2002 
 
TAL1: it belongs to the family of transcription factors helix-loop-helix 
(bHLH) and is believed to be involved in the erythroid commitment. In the 
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cells of murine erythroleukemia TAL1 acts as a transcriptional repressor 
being associated with the corepressor mSin3A and the histone deacetylase 
HDAC1; thereby inhibits erythroid differentiation.  
 
GATA: the GATA family consists of seven zinc-finger proteins including 
GATA1 and GATA2 which seem to have a fundamental role in 
erythropoiesis; knock-out experiments for these two transcription factors 
show an arrest of erythroid differentiation and maturation. [42] [43]  
GATA2 is involved in proliferation, differentiation and survival of early 
hematopoietic cells, where it is highly expressed. The amount of this factor 
decreases during maturation of circulating cells. It seems that the 
mechanism of action of GATA2 is to increase the responsiveness to 
various growth factors and in particular to the c-kit ligand (SCF). [44]  
GATA1 is especially important for erythroid differentiation and maturation: 
its absence causes an arrest at the pro-erythroblast stage. The central 
motif of the binding site, containing the consensus sequence (A/T) GATA 
(A/G), is present in the promoters and enhancers of many erythroid-specific 
genes: globin genes, the receptor for erythropoietin and of the same GATA. 
[45] It is indeed likely that GATA1 negatively regulates GATA2 as the latter 
decreases with the increase of GATA1 during differentiation.  
 
EKLF (Erythroid Kruppel-Like Factor): it is an erythroid-specific 
transcription factor that allows the expression of the β globin gene by 
binding to the CACCC consensus sequence present in its promoter. This 
factor could also facilitate the interaction of the β globin gene promoter with 
the LCR, thereby contributing to the reduction of the expression of the γ 
globin gene during the globin switching. It was also recently shown that 
knockdown of EKLF1 reduces the levels of BCL11A and increases the γ/β 
globin ratio. It was then proposed that EKLF1 controls the globin switching 
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by directly activating the β globin gene and by indirectly repressing the 
expression of the γ globin gene. [46]  
 
SP1: it is a factor involved in the regulation of erythroid maturation. It has 
been hypotised that, by interacting with the GATA1 and binding to the LCR 
or to the promoter region of the γ globin gene, it could activate the 
transcription or interfere with the globin switching. [47]  
 
SOX6: it is a member of the transcription factors Sox (Sry-type HMG box) 
family, characterized by the presence of an HMG domain that recognizes 
the minor helix of the DNA. The ability of Sox proteins to bind to other 
transcription factors and to alter the DNA sequence, suggesting that they 
act as "architectural protein" probably by promoting the assembly of 
multiprotein complexes. Sox6 seems to act both as an activator and as a 
transcriptional repressor depending on the interaction with specific target 
sequences. [48] Recent studies indicate that the complete ablation of Sox6 
causes an alteration of erythropoiesis with the consequent release into the 
circulation of an increased number of fetal nucleated cells and leads to an 
increased expression of embryonic globin gene ε. In particular, it was 
suggested that Sox6 decreases the expression of the εγ globin gene during 
the murine erythropoiesis and it cooperates with BCL11A in the γ globin 
gene downregulation in adult erythroid cells. [49] Finally, it was recently 
demonstrated that the expression of Sox6 decreases during the final stages 
of erythropoiesis and how Sox6 is able to regulate its downregulation 
through a double bond within its own promoter. [48]  
 
BCL11A: it is transcription factor that acts as a repressor of  γ globin gene 
expression.  In fact, recent studies have shown that the knockdown of 
BCL11A results in an increased levels of γ globin. [50] The expression of 
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BCL11A varies during erythroid differentiation and during ontogeny. It is 
expressed at high levels and as a full-length active form in the adult stages 
when the γ globin gene is silent, while in the embryo and foetus its 
expression is lower and its shorter less active isoforms predominate. [51] 
 
Figure 3.6 : Mechanism of Action of BCL11A  
 
 
Source: Sankaran, “Transcriptional silencing of fetal hemoglobin”, Ann N Y Acad Sci, p. 65, 
2010 
 
BCL11A appears to regulate specifically the expression of the γ globin 
gene. In fact, it binds at chromatin level of the β globin locus interacting with 
the third hypersensitive site of the LCR and with distinct regions located 
between the Aγ and δ globin genes, and does not seem to tie the γ globin 
promoter. [50]  
Thanks to proteomic studies, it was shown how BCL11A is able to interact 
with different proteins: with NuRD, a complex of transcriptional repressors 
containing two histone deacetylases (HDAC1 and HDAC2), with the 
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transcription factor GATA1 and FOG by zinc –fingers bound, [52] and with 
the component of the nuclear matrix Matrin-3 (Figure 3.6.). It seems that 
through these interactions, BCL11A has a key role in the regulation of the 
switch from o to adult haemoglobin, as well as in the γ globin gene 
silencing in mature erythroid cells. For this reason, BCL11A constitutes an 
important therapeutic target for the activation of foetal haemoglobin (HbF) 
in patients with β thalassemia. 
 
3.2.3.  The Globin Swithcing 
The proliferation and erythroid maturation are characterized by a 
progressive increase in the production of haemoglobin (Hb). The structure 
of human haemoglobin changes during the development in order to satisfy 
the different needs of oxygen by the body. [53]  
The synthesis of haemoglobin is characterized by two main switches: the 
first, from embryonic to foetal Hb coincides with the transition from primitive 
haematopoiesis (which occurs in the yolk sac) to definitive haematopoiesis 
(in the foetal liver from the fourth month of pregnancy); the second, from 
foetal to adult Hb, that occurs in the perinatal period.  
The embryonic haemoglobin is formed by two ζ chains and two ε chains 
(ζ2ε2); foetal hemoglobin is composed by two γ chains and two β chains 
(γ2β2); finally, adult haemoglobin (HbA) is composed by two α chains and 
two β chains (α2β2). In the adult, in addition to HbA, which is the main form 
of haemoglobin (98%), there is also has a smaller portion of HbA2 (α2δ2, 
2%) and HbF (in trace amounts).  
 
The genes for α and β globin chains are located in clusters and arranged 
from 5’ to 3' end in the order in which they are expressed during 
development.  
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The α globinic cluster is located on chromosome 16 and is composed by 
the ζ embryonic gene, two copies of the gene α and two non-functional 
pseudogenes as well. The β globinic cluster is located on chromosome 11 
and is constituted by the embryonic gene ε, and by two copies of the gene 
γ that differ for one amino acid in position 136 (G or A) and by the δ and β 
genes that are expressed in adult.  
Upstream of the two globinic clusters there is a regulatory region called 
LCR (locus control region) for the cluster β and HS-40 for the cluster α. This 
region allows the transcriptional activation in sequence of the globin genes 
of each clusters. 
 
Figure 3.7:  the Globin Switching 
 
Source : Bauer D.E. et all “Reawakening fetal hemoglobin: prospects for new therapies for 
the β-globin disorders” Blood, October 11, 2012, 120 (15) 
 
The adjustment of the globin switch occurs primarily at the transcriptional 
level but its mechanisms are not yet fully known. Molecular studies have so 
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far shown that the transcription of the globin genes is regulated by protein-
DNA and protein-protein interactions. At the level of the promoter of each 
globin gene are present consensus sequences, such as TATA box, CCAAT 
box and CACCC box, which interacts with the LCR region and with the 
trans-activating factors to promote gene transcription.  
 
Studies of genome-wide association and linkage disequilibrium have shown 
that the variability of HbF levels, in β thalassemia patients and in healthy 
subjects, is at least in part genetically determined and these studies have 
allowed us to identify three main polymorphisms (QTL: quantitative trait 
loci) that explain 20-50% of the variability. Xmn1-HBG2, the HBS1L-MYB 
intergenic region on chromosome 6q23 and BCL11A on chromosome 
2p16. [54] In particular, for example, the polymorphism rs4671393 GG in 
place of the gene BCL11A is found to be associated with low levels of HbF 
and high levels of BCL11A, while the variant AA is associated with high 
levels of HbF and low levels of BCL11A. [52]  
 
A key role in the regulation of  the globin switching has been assigned:  
- To BCL11A, a potent silencer of HbF  
- To KLF1, the transcription factor that activates BCL11A  
-  
As previously reported, BCL11A is associated with different transcription 
factors in order to compose a multiprotein complex, including NuRD, 
GATA1 and SOX6, important for the suppression of the γ globin gene [50] 
(Figure 3.6).  
KLF1 seems to have a dual role: it diminishes the γ globin gene expression 
by stimulating the transcription of the β globin gene by activating the 
repressor BCL11A with further silencing of the γ globin expression. [55]  
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cMyb could repress the expression of the γ globin through the activation of 
BCL11A mediated KLF1. [55] [56] [57] 
Finally multiprotein complexes containing the PRMT5 arginine 
methyltransferase, the enzyme demethylating DNMT3A, the 
serine/threonine kinase CK2alpha and components of NuRD, occupy the γ 
globin promoter in order to methylate and make it transcriptionally inactive.  
 
In Figure 3.8 it is shown a possible mechanism of interaction between the 
various transcription factors cooperating to decrease the expression of the 
gene γ globin. All of these factors represent potential new therapeutic 
targets to reactivate the γ globin gene and increase the levels of HbF in 
patients with β thalassemia. [56] 
 
Figure 3.8 : A Possible Model of Globin Genes Regulation 
 
                          
 
 
 
 
 
 
 
 
 
Source: Bauer D., Orkin S., “Update on fetal hemoglobin gene regulation in 
hemoglobinopathies”, Curr Opin Pediatrics, p.5, 2011 
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AIMS 
A new perspective to amplify the knowledge of the molecular β-thalassemia 
is based on the possibility of studying different molecules participating in 
the huge pathway that is the iron metabolism.  
One of these molecules is the FERROPORTIN. 
In the literature, there are many works mostly conducted in vivo, cell lines, 
or not using the beta thalassemia as models of ineffective erythropoiesis 
and iron overload. 
It is our interest to check what has been said in the literature, not through 
the cell lines, but using an ex vivo model, which consists in cultured 
erythroid differentiation obtained from CD34+ precursors collected from the 
peripheral blood of healthy subjects and non – transfusion dependent 
thalassemia patients.  
To check how the ferroportin is regulated, for each framework 
(physiological and thalassemia), are set up six conditions: standard, iron 
depletion (using the chelator Desferal), iron saturation (by Iron Ammonium 
Citrate), with heme bound iron (by adding Hemin), with heme iron free (by 
using SnPP IX). Plus, for the control cell culture is set another condition in 
order to simulate the oxidative stress by adding Hydrogen Peroxide. 
These components were added to cell cultures at day 0 and 7 and it has 
been evaluated their effect on:  
- growth and cell viability;  
- the trend of the expression of FPN isoforms and their effect on the 
intra and extracellular iron concentration, measured respectively by 
RealTime - PCR and an Iron Assay kit. 
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MATERIALS AND METHODS 
1. Cell Cultures 
1.1.   CD34+ cell cultures from peripheral blood 
Mononuclear cells derived from peripheral blood are enriched in CD34+ 
cells with an immunomagnetic method by using magnetic beads binding the 
antibody anti-CD34+ (Mini & Midi MACS Separation System, Miltenyi 
Biotech).  
 
Separation of mononuclear cells  
The peripheral blood of healthy subjects, provided by the Blood Transfusion 
Centre after routine inspections, is diluted 1:1 with PBS 1X (phosphate 
buffered saline, GIBCO BRL), layered on a gradient of Limphoprep 
(Nycomed - Pharma) in the ratio 2:1 and centrifuged for 20 minutes at 
1980xg at room temperature. The ring of mononuclear cells thus formed, is 
carefully collected, transferred into 50 ml tubes and centrifuged at 300xg for 
10 minutes. To eliminate the mature erythrocytes possibly present, the 
pellet is resuspended in 50 ml of lysis buffer (155 mM NH4Cl, 10 mM 
KHCO3, 0.1 mM EDTA), incubated for 5-7 minutes at room temperature 
and centrifuged at 300xg for 10 minutes. There are two washes at 300xg 
for 10 minutes each, by resuspending the pellet in 50 ml of PBS 1X; in 
order to eliminate the platelets. At the conclusion of the second wash, the 
pellet is diluted in 10 ml of  PBS 1X for cell counting.  
 
Immunomagnetic separation of CD34 +  
The cells are resuspended in Buffer B 1X (1x PBS, BSA 0.5%, EDTA 2mM, 
H2O) (300μl / 100x106 cells) and incubated for 30 minutes at 4°C with 
magnetic beads anti-CD34+  (100µL / 100x106 cells) (MACS Micro Beads) 
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and FcR blocking reagent that inhibits the non-specific binding between 
cells and beads (100µL / 100x106 cells).  
The cell suspension is then passed through a column, previously hydrated 
with Buffer B 1X (1 mL for the MiniMACS column, 5 mL for the MidiMACS 
column), containing a magnetisable matrix and, in turn, inserted into a 
permanent magnet (MiniMACS Separation unit for cell concentrations up to 
2x108 cells; Midi MACS Separation unit for cell concentrations up to 2x109). 
In this way, the CD34+ cells bound to the beads are retained in the column 
and separated from the other non-labelled cells, which exceed the matrix. 
The column is then washed three times with Buffer B 1X (3x500 μl for the 
MiniMACS column, 3x3 ml for MidiMACS column), in order to completely 
remove the CD34- cells. Detaching the column from the magnet, the CD34+ 
are eluted with buffer B 1X (1 ml for MiniMACS column, 5 ml for MidiMACS 
column) with the aid of a plunger and recovered in a 15 ml conical tube, 
ready for the cell count.  
 
After cell counting, the CD34+ cells are washed and seeded at a 
concentration of 105 cells / ml in a medium consisting of:  
70% Mem-Alpha Medium (GIBCO, BRL)  
30% foetal bovine serum (GIBCO, BRL)  
1 U / ml recombinant human erythropoietin (r-HuEPO Euroclone)  
25 ng / ml stem cell factor (Peprotech)  
10 ng / ml interleukin-3 (Peprotech).  
The cells are incubated at 37°C in a humidified atmosphere of 5% CO2 for 
14 days. [58] 
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1.2.    Cellular Morphology Evaluation 
At the end of the cell culture, or at predetermined time intervals, the 
morphology is evaluated, and thus the degree of cell differentiation, by 
centrifuge 0.2x106 cells for 5 minutes at 350 rpm on a slide (Cytospin 
Shadon Elliot). For each cell culture two slides are prepared, one is stained 
with May-Grunwald mixture (eosin methylene blue solution containing more 
than 50% of methanol, SIGMA) - Giemsa (solution azure eosin methylene 
blue, SIGMA), the other with benzidine and then with May-Grunwald - 
Giemsa.  
 
Benzidine staining  
This coloration allows highlighting with a greenish colour in the presence of 
iron bound to heme in the cells examined.  
It's a great method to identify the stage of maturation and cell 
differentiation. 
 
Figure 1 : Mature Erythrocyte 
 
Figure 1: indicated by the arrow is possible to see a mature erythrocyte at 
day 14 of differentiation. Are highlighted in blue the nucleus and in green 
the cytoplasm rich of iron bound to heme 
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Staining with May-Grunwald - Giemsa  
This staining method permits the evaluation of the sterility of the culture and 
to analyse the morphology, through the binding of the dyes to the acid 
component (methylene blue) and basic (eosin) cells. The slides are 
covered with May-Grunwald filtered for 7 minutes (the methyl alcohol 
present in the solution fixing the spot), rinsed in water and then covered 
with Giemsa filtrate and diluted 1:16 (v / v) for 17 minutes. Finally, the 
slides are washed in water, dried and read under the immersion 
microscope. The nuclei appear in a  more intense purple compared to the 
cytoplasm.  
 
1.3. Analysis by flow cytometry  
The analysis by flow cytometry is used to determine the presence of 
membrane markers (CD34, CD45, glycophorin) by labelling with specific 
antibodies and to assess cell viability by incubation with propidium iodide, 
which penetrates the dead cells.  
The cells are harvested at days 0, 7 and 14 of culture, washed with PBS 1X 
(phosphate-buffered saline PBS; GIBCO) and resuspended at a 
concentration of 105 cells/100 uL. For the analysis of the membrane 
markers, cells are incubated for 25 minutes at 4°C with anti-CD71 (10μl, 
BectonDickinson), anti-CD45 (10μl, BectonDickinson) and anti-glycophorin 
(5uL, BectonDickinson). After incubation, the cells are centrifuged at 460 
rpm for 10 minutes and resuspended in PBS. For the assessment of cell 
viability, cells are incubated for two minutes with propidium iodide.  
The analysis is performed with a flow cytometer with 3 fluorescences 
(FACS, Becton Dickinson) at a wavelength of 480 nm using the Cell Quest 
software.  
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● Cell count  
The cell count is commonly performed with the Burker’s chamber. This 
consists of a microscope slide comprising a series of lines that form 
squares (hemocytometer). It is covered with a coverslip, resulting in a 
capillary chamber.  
The set of orthogonal lines define a number of areas and thus of volumes. 
The room is in fact divided into 9 quadrants in turn divided into smaller 
squares inside them.  
Applies a cell suspension of about 10µl in the chamber, and, looking 
through a microscope, count the cells of at least three quadrants. Usually is 
preferable choosing three fields on the diagonal in order to have a good 
statistical variability.  
It is then calculated the number of cells according to the following formula: 
n = 
  
  
 . F . V . 104 
Where: nc = viable cell counted; nq = number of squares counted; F = 
dilution factor, and V = volume in which the cells are resuspended  
 
Cell viability test  
The Trypan blue is a dye used in tests determining the cell viability. This 
dye allows to discriminate between viable cells and dead ones as it is a dye 
capable of stain dead cells selectively. The reason why this dye does not 
stain the live cells is found in the extreme selectivity of the cell membrane. 
Viable cells, having the membrane intact, do not allow the penetration of 
this dye in the cytoplasm; on the contrary, in the dead cells the stain 
penetrates easily, making them indistinguishable from the alive ones with a 
rapid microscopic analysis. The trypan blue is not able to distinguish 
apoptotic cells from necrotic cells. For the cell count with the Burker’s 
chamber, the cells are diluted with the dye in order to have a dilution factor 
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equal to 10 according to the following preparation: [70 µL of α - MEM; 20µL 
of trypan blue solution and 10μl of cell suspension].  
Then all the cells are counted (the bright and the blue ones).  
The percentage of viability is obtained by the ratio between the number of 
viable cells and the total number of cells:  
Viability = No. of live cell x 100 / number of total cells. 
 
2.    Genetic expression analysis 
2.1.  RNA extraction 
Total RNA is extracted from the cells using a mixture of guanidine 
isothiocyanate -phenols - chloroform, according to the method described by 
Chomczynski - Sacchi. The protocol is divided into several phases: lysis of 
the sample cell, the organic phase separation, precipitation, washing and 
solubilisation of RNA.  
 
Lysis of the cell sample  
The cells are washed three times with PBS 1X. To lyse them, the pellet is 
resuspended in a denaturing solution (solD, 500 μl/107 cells) consisting of: 
4M guanidine thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% 
laurilsarcosil, 0.1M β-mercaptoethanol. The guanidine thiocyanate inhibits 
the ribonucleases and then maintains the integrity of the RNA; as an added 
precaution, all the solutions are kept on ice.  
 
Separation of organic phases  
Sodium acetate 2M, pH 4.5 (50μl/500μl solD), phenol saturated in water 
(400μl/500μl solD) and CIAA (chloroform - isoamyl alcohol 24:1 v/v) (100 
uL/500μl solD) are added to the suspension obtained after solubilization 
with the solD. The solution is then mixed by inversion and incubated on ice 
for 15 minutes. After incubation, the sample is centrifuged for 10 minutes at 
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10.000 rpm at 4°C. In this way two phases are formed: an upper aqueous 
and lower organic one; RNA is contained exclusively in the aqueous phase, 
while DNA and proteins are present in the interphase and organic phase.  
 
Precipitation of RNA  
The aqueous phase is recovered and transferred into a new eppendorf; 
RNA is then precipitated by adding a volume of isopropanol equal to that 
recovered (about 600µL) and incubating at -20°C for one hour. The sample 
is then centrifuged for 10 minutes at 13.000 rpm at 4°C.  
 
Washing and solubilization of RNA  
The pellet is resuspended in 500µL of 70% ethanol (diluted in water treated 
with diethylpyrocarbonate 7mM for the inhibition of ribonuclease [DEPC-
H2O]) and centrifuged for 10 minutes at 13.000 rpm at 4°C. Finally the 
pellet is left to air dry, and then resuspended in 20μl of DEPC-H2O and 
stored at -80 ° C. 
 
2.2.  Determination of RNA concentration and its purity evaluation 
The purity and integrity of the extracted RNA are evaluated by 
electrophoresis in 0.7% agarose gel (agarose dissolved in TBE 1X) or by 
analysis of the ratio of the absorbance at a wavelength of 260 nm and 280 
nm. The RNA is considered sufficiently pure when is possible to see three 
sharp bands corresponding respectively ribosomal RNA 28S, 18S and 5S 
by analysing the gel at the ultraviolet light; excessive background noise is 
an indication of the high level of RNA degradation. Similarly, the 
preparation is considered pure if the ratio 260/280 nm has a value between 
1.6 and 1.8; a lower value indicates the presence of contaminating proteins 
or phenol.  
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The concentration of the RNA sample is determined by spectrophotometric 
analysis by measuring the absorbance at a wavelength of 260 nm. 
Considering that an optical density of 1 corresponds to 40 µg/ml of RNA, 
the concentration of the sample is calculated according to the formula: 
C (µg/µl) = OD x F x 40/1000 
 
2.3.   RNA retrotranscription 
The messenger RNA (mRNA) present in the solution of total RNA extracted 
from the cells, are reverse transcribed into cDNA using as primers the 
random examers and as enzyme the reverse transcriptase of Moloney 
murine leukemia virus (MMLV) produced by a recombinant strain of E. coli.  
To perform the reverse transcription reaction, the protocol High Capacity 
cDNA Reverse Trascription kit from Applied Biosystems is used. To 1μg of 
total RNA the reagents are added to the final concentrations indicated in 
Table 1, in a final volume of 20μl. 
 
Table 1.   Retrotranscription reagents 
Reagents Final concentration 
Tampon (10X) 50 mM KCl, 10 mM Tris-HCl pH 8.3 
dNTP (x 4) 1 mM (x 4) 
Random examers 3 µM 
RNase Inhibitor 1 U 
Reverse 
Transcriptase 
2.5 U 
Final volume 20µL 
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All the reagents and the 1µg of RNA are added into the Eppendorf tubes 
and put into the thermocycler following this temperature protocol: 
- 70°C for 10 minutes with the aim to denature any secondary structures of 
RNA that may interfere with reverse transcription. 
- 25°C for 10 minutes 
- 37°C for 120 minutes 
- 85°C for 5 minutes. 
- 10°C overnight 
 
2.4.   Real-time PCR  
This technique is very sensitive and can be achieved by the use of 
nonspecific intercalating dyes (SYBR Green), or with probes labelled with 
fluorescent molecules (reporter) which bind specifically our RNA Target. In 
both cases, the Real-Time PCR quantifies the fluorescence emitted during 
each PCR cycle.  
In this study, the Real-Time PCR was performed by using TaqMan probes.  
The TaqMan probe is an oligonucleotide which, as the two PCR primers, is 
designed to be complementary to the target sequence. Presents at the 5' 
end a fluorophore called REPORTER (FAM in this case) and at the 3' end a 
molecule called QUENCER (MGB in this case) (Figure 2.1): 
 
Figure 2.1: TaqMan probe 
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In a configuration of this type, the molecule QUENCHER prevents the 
fluorescence emission by the REPORTER. During each PCR cycle, 
however, in the phase of extension of the DNA strand complementary to 
the target sequence, the enzyme Taq polymerase encounters the 5' end of 
the probe and performs, at first, an undermining of the latter, followed by 
the detachment of the REPORTER thanks to the exonuclease activity (5' > 
3') of the Taq. In this way the fluorophore in solution does not undergo the 
inhibition of the QUENCER anymore, and it is excited by the halogen lamp 
thus, emits fluorescence. According to this mechanism, the intensity of 
fluorescence increases with the concentration of the specific amplified for 
each reaction. All the pairs of primers used in this study have an annealing 
temperature of 60°C while for the probes is 10°C higher. The first probes 
produced, usually 30-35pb, the quencer absorbed and emitted 
fluorescence at the same time, in the last generation probes, such as those 
used in this study, the quencer has been replaced by the MGB (minor 
groove binder) that does not emit fluorescence and that is still to the minor 
groove of DNA and it increases the Melting temperature and therefore 
allowing the use of smaller probes (15-20bp) that allow to reduce the length 
of the amplicon. 
 
The Real Time PCR Plate Preparation 
Each plate for Real-Time PCR consists of 96 wells in which are deposited 
22.5µL of MIX and 2.5µL of cDNA (50 ng) diluted in water by a factor of 1.5.  
The MIX is thus prepared for each sample:  
• 12.5µL of Universal PCR Master Mix (2X) (Applied Biosystems) 
containing: buffer, Taq polymerase, nucleotides  
• 8.75µL of RNase free H2O  
• 1.25µL of PRIMER AND PROBE (20X)  
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The reaction mixture has a final volume of 25µl. For each gene analysed a 
specific MIX is prepared.  
The plate thus prepared, is covered with an optical adhesive that lets the 
light from the lamp in order to excite the fluorophore but prevents the 
evaporation of samples during PCR. The plate is then centrifuged at 900 
rpm for 5 min to remove any bubbles formed during preparation. 
Meanwhile, the program is set for the analysis.  
Each sample was analyzed in triplicate. For the relative quantification of 
gene expression we use the mathematical model based on the calculation 
of ΔΔCt using as internal standard the normalizer gene GAPDH and as 
calibrator the level of expression of the gene in the control culture not 
treated with the various drugs.  
 
Protocol for Real Time PCR  
● 1 cycle: 95°C for 10' initial denaturation  
● 40 cycles: 95 C for 15 " denaturation  
● 60°C for 1' extension and annealing 
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Figure 2.2 : PCR amplification curve 
 
The fluorescence is recorded during the extension phase.  
The molecular analysis in vitro was performed for the genes FPN1A and 1B 
starting from CD34+ cells obtained from liquid cultures treated with iron 
chelator, FeAMCit, H2O2, SnPP IX and Hemin. All molecular analyses were 
conducted on the samples treated with the various concentrations of 
compounds and their respective controls at days of culture 7 and14.  
All the operations relating to measurements and analysis are performed 
under the control of a software (SYSTEM SOFTWARE SDS) managed by a 
personal computer.  
The program automatically calculates:  
1. the baseline fluorescence indicating the number of cycles in which the 
instrument does not record any fluorescence;  
2. the threshold line, fluorescence value below which do not consider 
truthful data;  
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3. the threshold cycle (Ct), specific for each sample that identifies the value 
of the PCR cycle in which the curve intersects the line in the exponential 
phase threshold. Over the sample reaches the threshold to a lesser cycles 
of PCR is more concentrated and therefore expressed.  
Moreover, the software normalizes the data of target genes (FPN) 
compared to endogenous genes (β-actin or GAPDH) and calibrates them to 
a reference value (for our particular case it is the untreated control) and 
calculates:  
● The ΔΔCt, ie the difference between the ΔCt (= Ct target - Ct 
housekeeping), respectively, of the analysed samples and the calibrator 
(control).  
● The RQ (= 2-ΔΔCt), which indicates how many times the target gene is 
more or less expressed than the calibrator (Figure 2.3). 
 
Figure 2.3: Real Time – PCR Amplification Plot 
 
 
3. Iron Assay Kit 
The kit used for the intra and extracellular iron detection is the Iron 
Colorimetric Assay Kit (Biovision, San Francisco, CA) 
Procedure: 
For the intracellular iron 
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1) 1x106 cells are lysed in 20µL of Potassium Phosphate buffer (KP), 
incubate for 10’ at -20°C and then centrifuged at 2000rpm for 10’ 
2) Take the supernatant and the remaining pellet is lysed in 20µL of 
IRON BUFFER and centrifuged at 16000rpm for 10’ 
3) Take all the supernatant and put 10µL of each in a 96 well plate in 
order to have 0.5x106/10µL of lysed cells in each well (each 
samples is studied in duplicate) 
4) Prepare the standards using the standard solution from the kit (0 – 2 
– 4 – 6 – 8 – 10) 
5)  Each well is brought to the final volume of 50µL with the IRON 
BUFFER 
6) Prepare the blank for the KP (10µL of KP plus 40µL of IRON 
BUFFER) 
7) Add to each samples and to the standards as well, 2,5µL of IRON 
REDUCER  
8) Leave 30’ in the dark at room temperature 
9) Add to each samples and to the standards as well 50µL of IRON 
PROBE 
10) Leave 3 hours in the dark at room temperature 
11) Read the plate at 540nm 
 
For the extracellular iron 
1) The standards preparation is the same of the intracellular iron 
2) Thaw the supernatants and put 50µL of each samples in a 96 well 
plate 
3) Prepare the blank (in this case is 50µL of alpha – MEM) 
At this point, follow the procedure written above, starting from the 
point 7 
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Figure 3.1 Example of the Iron standard curve 
 
 
 
All the results should be normalized on the cell number in order to have the 
right value of iron concentration.  
 
4. Compounds Used 
 
- DESFERAL (deferoxamine mesylate, DFO; Biofutura Pharma SpA)  
Are dissolved 66 mg of compound  in 2.5mL PBS 1X to obtain a 
concentration of 40mM, this is then diluted to a 20 mM 
concentration. This solution is added to the cells at a final 
concentration of 10μM and 4 µM.  
 
Deferoxamine (DFO) forms complexes with the trivalent ions of Fe 
and Al: the formation constants of the complexes are, respectively, 
1031 and 1025. The affinity of DFO for divalent ions such as Fe++, 
Cu++, Zn++, Ca++ is substantially smaller (formation constant of the 
complex is 1014 or lower). The chelation occurs with molar ratio 1: 
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1, it means that 1 g of DFO can theoretically bind 85 mg of trivalent 
iron or 41 mg of trivalent aluminium.  
 
Thanks to its chelating properties, DFO can bind free iron both into 
plasma and into the cells, forming the complex ferrioxamine (FO). 
The urinary excretion of FO is derived mainly from the turnover of 
plasma iron, while the iron present in the feces mainly reflects the 
intrahepatic chelation. The iron can be chelated by ferritin and by 
the hemosiderin, but is relatively low at clinically relevant 
concentrations of DFO.  
 
The DFO does not mobilize, however, the iron content in transferrin, 
haemoglobin or other substances containing a heme group. 
 
- FERRIC AMONIUM CITRATE (FeAmCit / FAC; Sigma) 
650 mg of compound are dissolved in 5mL of PBS 1X to obtain a 
concentration of 0.4M, this is subsequently diluted to a 
concentration of 20 mM. This solution is added to the cells at a final 
concentration of 100 µM. 
 
- HEMIN CLORIDE (Sigma) 
2.2 mg of powder are dissolved in a solution composed of 100µL of 
NaOH and 200μL of media, resulting in a concentration of 11mM, 
this is subsequently diluted with PBS 1X to the concentration of 
5,55mM. This solution is added to the cells at final concentrations of 
20 and 10µM. 
 
- PROTOPORFIRIN IX DICLORIDE (SnPP IX; Frontier Scientific) 
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20 mg of powder are dissolved in a solution composed of 1064µL of 
NaOH 1M, resulting in a concentration of 25mM, this is 
subsequently diluted with PBS 1X to the concentration of 10mM and 
4mM. These solutions are added to the cells at final concentrations 
of 50 and 20µM. 
 
- HYDROGEN PEROXYGEN (H2O2; J.T. Baker) 
Diluted the 33M stock solution with water in order to obtain the 
20mM. Add this one to the cell culture in order to have a final 
concentration of 0.1mM 
 
5. Statistical Analysis 
All the significances are calculated by using the T test 
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RESULTS 
1. FERROPORTIN 1A and 1B analysis in control cell cultures  
CD34+ cells from healthy donors were cultured under conditions that 
stimulate erythroid differentiation. The culture medium contains, in fact, 
cytokines such as stem cell factor (SCF), interleukin 3 (IL-3) and 
erythropoietin (Epo). The cells were cultured for 14 days.  
The cells were analysed at different days of culture to assess growth and cell 
viability, morphology, gene expression and protein assay.  
For each condition three independent cell cultures were arranged, the results 
shown are the average of these three. 
 
1.1 Cell growth and viability analysis 
Growth and viability were assessed at different days of cell culture (0, 7, and 
14). 
 
Chart 1: cell growth of the control culture analysed at days 0, 7, 14 
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From the chart is possible to see a neat cell growth from 0.1x106 cells/mL at 
day 0, to 2.09x106 cells/mL at day 14, obtaining an increase of the cell 
number 21 times superior. 
 
Chart 2: analysis of the cell viability at days 0, 7, 14 of the CTRL cell culture 
 
The control cell cultures present an high viability during the entire erythroid 
differentiation process, in fact, the range of the viability percentage is 
between 100 and 96 %. 
 
1.2 Morphology 
 
Figure 1: mature erythroblast at day 14 of the cell culture 
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The figure shows a mature erythroblast at the end of its differentiation 
process. It is possible to see the round and regular shape of the cell. 
 
1.3 Analysis of the FERROPORTIN 1A and 1B expression during the 
erythroid differentiation 
The gene expression of FERROPORTIN isoforms was assessed at days 0, 
4, 7, 11 and 14 of the cell culture through the method of real - time PCR from 
cDNA obtained by reverse transcription of RNA extracted from cells of each 
condition.  
The results of the analysis were converted to charts that explain when and 
in which quantities our genes of interest were expressed during the 
differentiation, compared to an endogenous gene called housekeeping, 
which was the GAPDH.  
The values of expression of each ferroportin isoform are reported as the 
relative percentage on the 100% of the total ferroportin (the total ferroportin 
is calculated by summing the RQ = 2-ΔCt of each isoforms and then converted 
to a percentage of 100%). 
  
Chart 3: genic expression of FPN isoforms during erythroid differentiation 
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From the chart, it is clear that the expression of FPN1B is very low in the 
early days of culture and increases at day 7 (pro erythroblasts) and then 
decreases again at day 14 (mature erythroblasts).  
The FPN1A has the opposite trend: is high at the precursors stage (day 0), 
then decreases at day 7 and increases again at day 14. 
All the increasing and decreasing values are statistically significant: 
* p < 0.05 day 7 vs day 0 
° p < 0.05 day 14 vs day 7  
 
1.4 Intracellular and extracellular iron levels during differentiation 
 
Chart 4: intra and extracellular iron levels at days 0, 7, 11, 14 in control cultures 
 
The iron level measurement was obtained by using a colorimetric Iron Assay 
Kit at different days of culture. There is not the extracellular iron value at day 
0 since there is not culture supernatant, but just plasma from the peripheral 
blood; thus, it can be difficult comparing the iron levels between plasma and 
cell culture supernatants because they are not the same materials. 
The chart confirms what was observed at the genetic level: a decrease of the 
1A iron related isoform at day 7 consist in an increase of intracellular iron 
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and, on the other way round, an increase of ferroportin 1A at day 14 is linked 
to a major iron export, thus, a decrease of intracellular iron. 
The increase of the expression of FPN1B at day 7 can be justified by the fact 
that at this stage the erythroblast need iron for the haemoglobin synthesis, 
thus is important to have an isoform non - iron related in order to guarantee 
the presence of the intracellular iron without exporting it.  
The decrease of intracellular iron from day 7 to day 14 is statistically 
significant: p <0.05 
 
2. FERROPORTIN 1A and 1B analysis in NTDT cell cultures  
CD34+ cells from NTDT patients were cultured under conditions that 
stimulate erythroid differentiation. The culture medium contains, in fact, 
cytokines such as stem cell factor (SCF), interleukin 3 (IL-3) and 
erythropoietin (Epo). The cells were cultured for 14 days.  
The cells were analysed at different days of culture to assess growth and cell 
viability, morphology, gene expression and protein assay.  
For each condition three independent cell cultures were arranged, the results 
shown are the average of these three. 
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2.1 Cell growth and viability analysis 
Growth and viability were assessed at different days of cell culture (0, 7, 14).
 
Chart 5: cell growth analysis at day 0,7,14 of NTDT cultures not treated 
 
From the chart is possible to see a neat cell growth from 0.1x106 cells/mL at 
day 0, to 3.0x106 cells/mL at day 14, obtaining an increase of the cell number 
30 times superior. 
 
Chart 6: analysis of the cell viability at days 0, 7, 14 in NTDT cell cultures 
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The NTDT cell cultures present an high viability during the entire erythroid 
differentiation process; in fact, the range of the viability percentage is 
between 100 and 96,6 %. 
 
2.2 Morphology 
 
Figure 2: NTDT erythroid cells morphology at day 14 of culture 
 
From this picture is possible to see erythroblast cells at day 14 of culture. 
These cells have irregular shapes and contours, despite the fact that all cells 
are at day 14, the benzidine staining indicates that not all of them are at the 
same stage of maturation and differentiation (see cells marked with arrows).  
 
2.3 Analysis of the FERROPORTIN 1A and 1B expression during the NTDT 
erythroid differentiation 
The genetic expression of FPN 1A and 1B was evaluated at day 0, 7 and 14 
of the cell culture. The values of each isoform expression are reported as the 
relative percentage on the 100% of the total ferroportin (the total ferroportin 
is calculated by summing the RQ = 2-ΔCt of each isoforms and then converted 
to a percentage of 100%). 
The results represented the mean of three independent cell cultures. 
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Chart 7: FPN 1A and 1B expression during the NTDT erythroid differentiation 
 
From the graph, it is clear that the expression of FPN1B is low in the early 
days of culture (only 20%) and increases at day 7 (pro erythroblasts) and 
then decreases again at day 14 (mature erythroblasts).  
The FPN1A has the opposite trend: is high at the precursors stage (day 0), 
then decreases at day 7 and increases again at day 14. 
All the increasing and decreasing values are statistically significant: 
° p < 0.05 day 14 vs day 7  
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2.4 Intracellular and extracellular iron levels during NTDT differentiation 
  
Chart 8: intra and extracellular iron levels at days 7 and 14 in NTDT cultures 
 
The iron level measurement was obtained by using a colorimetric Iron Assay 
Kit at different days of culture  
The chart confirms what was observed at the genetic level: the increase of 
the FPN1A expression at day 14 causes a decreasing of intracellular iron.   
The decrease of intracellular iron from day 7 to day 14 is statistically 
significant: p <0.05 
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3. Comparison between CTRL and NTDT   
3.1 Ferroportin 1A and 1B expression in CTRL and NTDT cell cultures  
 
 
Chart 9 : comparison of the two FPN isoforms between CTRL and NTDT conditions during 
the erythroid differentiation 
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In these charts are compared the values of FPN1A and 1B expression during 
the erythroid differentiation in CTRL and NTDT cell cultures. 
It is possible to see that the FPN1B is the more expressed isoform in NTDT 
condition, especially at the beginning and at the end of the erythropoietic 
process (see chart 9B). While the ferroportin 1A is the predominant isoform 
in the CTRL cell cultures, even if the difference of expression between the 
isoform 1B is not so high (see chart 9A). 
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3.2 Intracellular and extracellular iron levels during differentiation in CTRL 
and NTDT cell cultures 
 
 
 
Chart 10 : comparison of  intra and extracellular iron levels between CTRL and NTDT cell 
cultures 
  
The charts represent the intra and extracellular iron levels at two different 
stages of cell culture ( day 7 / pro erythroblasts,  and day 14 / orthochromatic 
cells) in CTRL and NTDT conditions. 
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The chart 10A shows that, at day 7,  the intracellular iron levels are higher in 
CTRL cultures compared to the NTDT ones, while at the end of the 
erythropoiesis, the intracellular iron levels are the same in both conditions. 
The chart 10B shows the extracellular iron levels, and it is possible to see an 
inverted trade compared to the intracellular ones. In fact, at day 7, the iron 
levels are the same in both conditions, while at day 14 the extracellular iron 
levels are higher in the CTRL cell cultures. 
 
4. Analysis of the FPN1A and 1B in different cell culture conditions  
4.1. Analysis of the FPN1A and 1B in CTRL and NTDT cell cultures in 
condition of iron depletion and iron overload 
 
CTRL cell cultures 
4.1.1 Cell growth and viability  
CD34+ cells are cultured under conditions previously described.  
At day 0 of the cell culture, Ferric Ammonium Citrate (FAC) with a 
concentration of 100µM and the iron chelator (Desferal DFO) at 
concentration of 4mM were added. 
To observe if the differentiation took place according to the protocol, different 
evaluations of growth and viability at day 0, 4, 7, 11 and 14 were taken.  
When drugs or chemicals compounds such as iron chelator and FAC are 
added to the cells culture media, the evaluation of the growth and viability is 
important, especially when these treated condition are compared to the 
untreated control, allowing assessing the effect of the drugs in question.  
The data represent the average of three independent cultures. 
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Chart 11: evaluation of the cellular growth in cell cultures treated with DFO 4µM and FAC 
compared to the untreated condition during the differentiation 
 
From the chart, it can be observed that, until day 7, all conditions have an 
increasing trend; only the condition with the addition of FAC has a growth 
higher than the control, while the addition of DFO reduces growth compared 
to the control.  
At day 14 the FAC condition has a greater growth than the control one, while 
the DFO condition presents, compared to the untreated, a lower growth.  
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Chart 12: evaluation of the viability of the cell culture treated with DFO and FAC during the 
differentiation 
 
The cell viability of the culture is in the range between 100 and 80% and the 
viability of the FAC condition totally overlap with the untreated one.  
 
4.1.2 Cell morphology of DFO and FAC conditions 
A                                                                B 
 
Figure 3: morphology of erythroblasts treated with DFO (A) and FAC (B) 
 
From the pictures, it is possible to see that the culture treated with the 
chelating agent (Figure 3A) has the cells larger, less differentiated. The 
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culture treated with iron (Figure 3B) shows the cells more similar 
morphologically to the mature erythroblasts of the untreated control; plus, the 
benzidine staining indicates a significant increase of intracellular heme iron 
bound. 
 
4.1.3 Analysis of the FPN1A and 1B expression in iron depletion and iron 
overload cell cultures   
The expression of both ferroportin isoforms has been evaluated at day 14 of 
cell cultures at three different conditions: untreated, DFO, FAC. 
The results are the means of three independent cell cultures.  
 
Chart 13: FPN1A and 1B expression at day 14 of cell culture, in untreated, DFO and FAC 
conditions 
 
From the chart is clear that the ferroportin isoforms do not change their 
expression if the cells are treated with DFO or FAC in comparison to the 
untreated condition. 
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4.1.4 Analysis of the intra and extracellular iron levels in iron depletion and 
iron overload cell cultures   
The iron level measurements was obtained by using a colorimetric Iron 
Assay Kit 
 
Chart 14: intra and extracellular iron levels in CTRL cell cultures treated with FAC 
 
The intracellular iron level does not change between the FAC and untreated 
conditions. There is a consistent increase of extracellular iron in the FAC 
condition compared to the untreated (p < 0.05). This it might be related with 
the possibility that not all the FAC is absorbed by the cells, causing a high 
presence of iron into the supernatant. 
 
NTDT cell cultures 
4.1.5 Cell growth and viability  
CD34+ cells are cultured under conditions previously described.  
At day 0 of the cell culture, Ferric Ammonium Citrate (FAC) with a 
concentration of 100µM or the iron chelator (Desferal DFO) at concentration 
of 4mM were added. 
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To observe if the differentiation took place according to the protocol, different 
evaluations of growth and viability at day 0, 7, and 14 were taken.  
When drugs or chemicals compounds such as iron chelator and FAC are 
added to the cells culture media, the evaluation of the growth and viability is 
important, especially when these treated conditions are compared to the 
untreated control, allowing assessing the effect of the drugs in question.  
The data represent the average of three independent cultures. 
 
 
Chart 15: cell growth evaluation during cell differentiation in NTDT cell cultures treated with 
DFO 4µM and FAC compared to the untreated condition 
 
The graph shows that at day 7 and 14 the cell growth of the treated conditions 
is lower compared to the control one. The growth value of the DFO condition 
is significantly lower, while the condition with FAC shows a growth value 
intermediate between the control and the Desferal.  
 
0
1
2
3
4
5
6
0 7 14
ce
ll
s 
n
u
m
b
er
 x
1
0
^
6
 /
 m
l
Days of culture
NTDT growth in iron depletion & overload
U DFO FAC
 91 
 
 
Chart 16: NTDT cell viability evaluation during cell differentiation in cell cultures treated with 
DFO 4µM and FAC compared to the untreated condition 
 
The FAC condition shows a completely overlap with the untreated one and 
the range of vitality is between 100 and 92; while the DFO condition shows 
a little of cellular sufferance with a range of percentage of viability between 
100 and 75. 
 
4.1.6 Morphology of NTDT cells treated with FAC  
 
Figure 4: NTDT cells at day 14 untreated and treated with FAC  
 
0,0
20,0
40,0
60,0
80,0
100,0
120,0
0 7 14
%
Days of culture
NTDT viability in iron depletion & overload
U DFO FAC
92 
 
The picture shows that the erythroblast cells treated with FAC (figure 4B) are 
more little compared the untreated ones (figure 4A). The fact of seeing 
agglomerations of minute cells leads to the conclusion that these ones have 
entered into apoptosis due to the iron overload simulated by adding FAC. 
 
4.1.7 Analysis of the FPN1A and 1B expression in iron depletion and iron 
overload cell cultures   
The expression of both ferroportin isoforms has been evaluated at day 14 of 
cell cultures at three different conditions: untreated, DFO, FAC. 
The values of the genetic expression of the ferroportin isoforms are shown 
as percentage. 
The results are the means of three independent cell cultures.  
 
Chart 17: FPN1A and 1B expression in NTDT at day 14 of cell culture, in untreated, DFO and 
FAC conditions 
 
From the chart is clear that the ferroportin isoforms do not change their 
expression if the cell cultures are treated with DFO and FAC in comparison 
to the untreated condition. 
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4.1.8 Analysis of the intra and extracellular iron levels in iron depletion and 
iron overload cell cultures   
The iron level measurements was obtained by using a colorimetric Iron 
Assay Kit 
 
Chart 18: intra and extracellular iron levels in CTRL cell cultures treated with FAC 
 
The intracellular iron level does not change between the FAC and untreated 
conditions. There is a consistent increase of extracellular iron in the FAC 
condition compared to the untreated one (fold increase: 6.25). As it has been 
already said for the CTRL cell cultures, the increase of extracellular iron 
concentration in the FAC condition could be related with the possibility that 
not all the FAC is absorbed by the cells, causing a high presence of iron into 
the supernatant. 
 
 
 
 
11690 10020
61862
387130
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
U FAC
Ir
o
n
 u
M
Iron levels
intra
extra
94 
 
4.2. Analysis of the FPN1A and 1B in CTRL and NTDT cell cultures at the 
presence of free iron heme and heme iron bound 
 
CTRL cell cultures 
4.2.1 Cell growth and viability  
CD34+ cells are cultured under conditions previously described.  
At day 0 of the cell culture, the compounds Protoporfirin IX (SnPPIX, iron free 
heme) at the concentration of 50 and 20µM and the Hemin (iron bound to 
heme) at the concentration of 20 and 10µM were added.  
To observe if the differentiation took place according to the protocol, different 
evaluations of growth and viability at day 0, 7 and 14 were taken.  
When drugs or chemicals compounds such as protoporfirins and hemin are 
added to the cells culture media, the evaluation of the cell growth and viability 
is important, especially when these treated conditions are compared to the 
untreated control, allowing assessing the effect of the drugs in question.  
The data represent the average of three independent cultures. 
 
Chart 19: evaluation of the cellular growth in cell cultures treated with SnPPIX and Hemin 
compared to the untreated condition during the differentiation 
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All the conditions show an increase of cell growth during the erythroid 
differentiation. At day 14 is possible to see that the conditions with the high 
concentration of SnPP IX and Hemin show a cell increase less than the 
untreated condition. 
 
 
Chart 20: evaluation of the viability of the cell culture treated with SnPPIX and Hemin during 
the differentiation 
 
All the compounds show a cell viability similar to the untreated condition; all 
the values are between 100 and 94,6. 
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4.2.2 Cell morphology of SnPPIX and Hemin conditions 
 
 
 
 
 
 
 
 
 
Figure 5: Cell morphology of day 14 of CTRL cell culture treated with SnPP IX and Hemin 
 
The picture 5 shows five panels in which are represented the Untreated, 
SnPP IX 50µM, 20µM, the Hemin 20µM and 10µM conditions (5A, 5B, 5C, 
5D and 5E respectively). 
All the treated conditions show the same type of mature and differentiate 
cells as the untreated one; it means that the adding of those compounds to 
the cell cultures does not affect the erythroid differentiation process.  
 
4.2.3 Analysis of the FPN1A and 1B expression at the presence of free iron 
heme and heme iron bound 
The expression of both ferroportin isoforms has been evaluated at day 14 of 
cell cultures at five different conditions: untreated, SnPPIX 50 and 20µM and 
Hemin 20 and 10µM. 
The results are the means of three independent cell cultures.  
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Chart 20: FPN1A and 1B expression at day 14 of CTRL cell culture, in untreated, SnPP 50, 
20µM and Hemin 20, 10µM conditions 
 
From the chart is clear that the ferroportin isoforms do not change their 
expression if the cell cultures are treated with both Protoporfirin IX and Hemin 
at different concentrations, compared to the untreated condition. 
 
4.2.4 Analysis of the intra and extracellular iron levels at the presence of free 
iron heme and heme iron bound 
The iron level measurements was obtained by using a colorimetric Iron 
Assay Kit 
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Chart 21: intra and extracellular iron levels at day 14 of differentiation, in CTRL cell cultures 
treated with SnPP 50, 20µM and Hemin 20, 10µM conditions 
  
Regarding the intracellular iron levels (chart 21A) there are not significant 
differences between the treated and the untreated conditions. It is possible 
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to notice a slight increase of iron intracellular in the SnPP 20µM condition 
(8692 µM of intracellular iron vs 6479 µM for the untreated). 
The chart 21B shows the extracellular iron levels. Observing the SnPP IX 
concentrations, it is possible to see a decrease of the martial levels in a dose 
– dependent manner; vice versa, there is an increasing of iron concentration 
into the supernatant at the condition treated with hemin, in a dose – 
dependent manner as well. 
 
NTDT cell cultures 
4.2.5 Cell growth and viability  
CD34+ cells are cultured under conditions previously described.  
At day 0 of the cell culture, the compounds Protoporfirin IX (SnPPIX, iron free 
heme) at the concentration of 50 and 20µM and the Hemin (iron bound to 
heme) at the concentration of 20 and 10µM were added.  
To observe if the differentiation took place according to the protocol, different 
evaluations of growth and viability at day 0, 7 and 14 were taken.  
When drugs or chemicals compounds such as protoporfirins and hemin are 
added to the cells culture media, the evaluation of the growth and viability is 
important, especially when these treated conditions are compared to the 
untreated control, allowing assessing the effect of the drugs in question.  
The data represent the average of three independent cultures. 
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Chart 23: evaluation of the cellular growth in cell cultures treated with SnPPIX and Hemin 
compared to the untreated condition during the differentiation 
 
All the conditions show an increase of cell growth during the erythroid 
differentiation. At day 14 is possible to see that both the Hemin and the SnPP 
IX 20µM shows values of cell growth major than the untreated, while the 
SnPP IX 50µM shows a cellular increase minor than the untreated. 
 
 
Chart 24: evaluation of the viability of the NTDT cell culture treated with SnPPIX and Hemin 
during the differentiation 
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From the chart is possible to see that all the compounds do not show cellular 
toxicity since all their viability values are overlapping the untreated ones 
(viability values range between 100 and 98). 
 
4.2.6 Morphology of NTDT cells treated with SnPP and Hemin  
 
 
 
 
 
 
 
 
Figure 6: NTDT cells at day 14 treated with SnPP and Hemin 
 
The picture 6 shows five panels in which are represented the Untreated, 
SnPP IX 50µM, 20µM, the Hemin 20µM and 10µM conditions in the NTDT 
cell culture (5A, 5B, 5C, 5D and 5E respectively). 
All the treated conditions show the same type of erythroid cells as the 
untreated one; it means that the adding of those compounds to the cell 
cultures does not affect the erythroid differentiation process as it has been 
already seen for the CTRL cell cultures. 
 
4.2.7 Analysis of the FPN1A and 1B expression at the presence of free iron 
heme and heme iron bound 
The expression of both ferroportin isoforms has been evaluated at day 14 of 
cell cultures at five different conditions: untreated, SnPPIX 50 and 20µM and 
Hemin 20 and 10µM. 
The values of genetic expression are shown as percentage. 
The results are the means of three independent cell cultures.  
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Chart 25: FPN1A and 1B expression in NTDT at day 14 of cell culture in untreated, SnPP 50, 
20µM and Hemin 20, 10µM conditions 
 
From the chart is clear that the ferroportin isoforms do not change their 
expression if the cell cultures are treated with both Protoporfirin IX and Hemin 
at different concentrations, compared to the untreated condition 
 
4.2.8 Analysis of the intra and extracellular iron levels at the presence of free 
iron heme and heme iron bound   
The iron level measurements was obtained by using a colorimetric Iron 
Assay Kit 
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Chart 26: intra and extracellular iron levels in NTDT cell cultures treated with SnPP IX 50, 
20µM and Hemin 20, 10µM 
 
The intracellular iron level (chart 24A) decreases in the treated conditions 
compared with the untreated one (2 fold decrease regarding all the SnPP IX 
and the Hemin 20µM conditions, 7 fold decrease regarding the Hemin 10µM 
condition). 
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The chart 24B represent the extracellular iron level: no much difference is 
observed between the untreated and the SnPP IX conditions, while a big 
change is notable between the control and the Hemin conditions where is 
possible to see a marked increase of iron present into the cell culture 
supernatant. The situation is different from the FAC condition previously 
described since the kit cannot measure the iron bound to different proteins 
such as heme.  
 
 
4.3. Analysis of the FPN1A and 1B in CTRL cell cultures under oxidative 
stress  
 
4.3.1 Cell growth and viability  
CD34+ cells are cultured under conditions previously described.  
To simulate the oxidative stress condition, hydrogen peroxide 0.1mM (H2O2) 
was added at every other days from day 0 to day 14 of the cell cultures. 
To observe if the differentiation took place according to the protocol, different 
evaluations of growth and viability at day 0, 7 and 14 were taken.  
When drugs or chemicals compounds such as the hydrogen peroxide are 
added to the cells culture media, the evaluation of the growth and viability is 
important, especially when these treated conditions are compared to the 
untreated control, allowing assessing the effect of the compounds.  
The data represent the average of three independent cell cultures. 
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Chart 27: evaluation of the cellular growth in cell cultures treated with H2O2 0.1mM compared 
to the untreated condition during the differentiation 
 
From the chart is possible to see that, even if there is an increase of cell 
number during the entire process of erythroid differentiation in both 
conditions, the adding of H2O2 causes a minor cell growth compared to the 
CTRL condition. 
 
Chart 28: evaluation of the viability of the cell culture treated with H2O2 0.1mM during the 
differentiation 
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From the chart is possible to see that the adding of H2O2 0.1mM does not 
cause cell toxicity. In fact, the cell growth in the condition under oxidative 
stress is almost the same of the untreated condition. The percentage values 
are between 100 and 93.7 %. 
 
4.3.2 Cell morphology of H2O2 0.1mM condition 
 
 
 
 
 
Figure 7: cell morphology at day 14 of CTRL cell culture treated with H2O2  
 
The figure 7A and 7B shows the erythroblasts morphology at day 14 of the 
untreated and the H2O2 0.1mM conditions. As we can see, there are no 
differences between the two panels; it means that the adding of hydrogen 
peroxide does not affect the erythroid differentiation. 
 
4.3.3 Analysis of the FPN1A and 1B expression under oxidative stress 
The expression of both ferroportin isoforms has been evaluated at day 14 of 
cell cultures. 
The results are the mean of three independent cell cultures.  
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Chart 29: FPN1A and 1B expression at day 14 of CTRL cell culture, in untreated and H2O2 
0.1mM conditions 
 
This chart shows a change in the FPN1A and 1B expression in the condition 
treated with H2O2 0.1mM compared to the untreated one. In fact, the ratio of 
the two isoforms goes from 2,7 : 1 for the control to 1 : 1 for the H2O2 0.1mM 
condition suggesting a possible role of the oxidative stress in the modulation 
of the FPN1B expression. 
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4.3.4 Analysis of the intra and extracellular iron levels under oxidative stress 
The iron level measurements was obtained by using a colorimetric Iron 
Assay Kit 
 
Chart 30: intra and extracellular iron levels at day 14 of differentiation, in CTRL cell cultures 
treated with H2O2 0.1mM 
  
Regarding the intracellular iron levels there is a slight increase of the ion 
concentration in the treated condition compared to the untreated one. It is 
possible to see a marked increase of extracellular iron levels into the H2O2 
0.1mM condition compared to the control.  
These results, taken together with the expression profiling of the ferroportin, 
suggest that under oxidative stress, there is a change of predominant 
ferroportin isoform expression (from 1A to 1B) suggesting a possible role of 
the ROS in the regulation of FPN1B expression. 
 
 
5573
14552
36859
110769
0
20000
40000
60000
80000
100000
120000
U H2O2
Ir
o
n
 u
M
Intra and extracellular iron levels
intra
extra
109 
 
DISCUSSION 
Thalassemia intermedia (TI) is a heterogeneous group of syndromes 
caused by a defect in the synthesis of β-globin chains and characterized by 
ineffective erythropoiesis and decreased production of red blood cells. The 
clinical manifestations of TI are the result of three key factors: ineffective 
erythropoiesis, chronic anaemia and iron overload. Unlike patients with 
thalassemia major (TM), in which iron overload is mainly due to the 
transfusion therapy, patients with TI accumulate iron mainly due to an 
increased intestinal absorption and to the ineffective erythropoiesis. [60] 
The pathophysiology of iron overload in TI and its toxicity are still not 
completely known. 
In recent years there have been major advances in our knowledge about 
the regulation of iron metabolism that have had implications for 
understanding the pathophysiology of some human disorders like β-
thalassemia and other iron overload diseases. However, little is known 
about the relationship among ineffective erythropoiesis, the role of iron-
regulatory genes, and tissue iron distribution in β-thalassemia.  
Regarding these last two points, there are many studies about the role of 
hepcidin for the regulation of iron metabolism in pathologic diseases such 
as the thalassemias, but less has been published about its ligand, the 
ferroportin. 
Ferroportin can be considered as a new protein since it has been almost 
fully described only in these last few years (by Cianetti and Zhang groups); 
for the first time in 2010 it has been demonstrated that the FPN is 
expressed even in the erythroblast cells [3] and not only in the 
macrophages, enterocytes and hepatocytes. 
From this new information it has been formulated the hypothesis that the 
erythroid ferroportin could participate in a pathway in which the red blood 
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cell communicates the iron need in order to expand the erythroid 
compartment ignoring the systemic iron levels. [3] 
Moreover, another one flanked this discovery: the ferroportin has two 
different isoforms; one iron responsive (FPN1A) and the other one that is 
not (FPN1B). 
It meant that even if the ferroportin had an important role in the iron 
metabolism; it could be regulated by other mechanisms as well and not 
only by iron.  
From this assessment, different lab groups tried to find which was the 
regulatory mechanism for the expression of the ferroportin and, in 
particular, of its isoforms. 
In the literature, it is possible to find many works on the study of the FPN1A 
in different cell types and cell lines. 
Cianetti and Marro hypothesized the role of heme in the regulation of the 
ferroportin 1A (but nothing has been said about the isoform 1B) [3][6]. 
Although those studies were conducted on macrophages and not on 
erythroid cells, they lead to an important conclusion: the iron recycling from 
heme involves a single transcription control mechanism that regulates 
heme catabolism, iron storage and detoxification as well as iron export in a 
coordinated manner. 
Zhang was the first to study the role of the isoform 1B in mice. These 
studies confirmed the expression of this isoform at the erythroid level; plus, 
the FPN1B was not repressed in situation of iron depletion suggesting a 
possible role of the FPN1B: this protein could make the erythroblast cells 
more responsive to the changes of the systemic iron levels compared to the 
intracellular ones. [5] 
In 2013 Chiabrando found another factor that could regulate the ferroportin 
expression: the Hypoxia Inducible Factor 2α (HIF2α). This study was 
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conducted in macrophages and enterocytes, but not in erythroid 
precursors. [61] 
From the time of its discovery to the present day, a lot of information about 
the ferroportin has been collected. In fact, now it is known that the 
expression of FPN is controlled by multiple mechanisms underlining the 
importance of precise regulation of iron export: 1) transcriptional control by 
haemoglobin; 2) alternative promoter usage in duodenal enterocytes and 
erythroid precursor cells; 3) translational control by the IRE/IRP system in 
response to iron levels; as well as 4) post-translational control by hepcidin 
and systemic iron requirements. How the regulation of FPN by the different 
stimuli is prioritized will be the subject of further investigation. 
Unluckily less is known about how the ferroportin is expressed and 
regulated in the thalassemia syndromes, more specifically, in non-
transfusion dependent thalassemia (NTDT). 
 
The principal aim of our work is to try to describe the role of ferroportin 
during human normal and pathological erythroid differentiation. Particular 
attention will be given to the NTDT in order to collocate the ferroportin in 
the huge puzzle such as the iron metabolism process and try to find a 
possible role in an environment where the iron metabolism is altered. 
 
In the literature the majority of the studies are conducted on cell lines and 
mouse models, hence, it is of relevant importance try to work out a study 
based on ex vivo culture systems in order to study erythroid differentiation 
in both physiological and thalassemia conditions. 
A method for the preparation of cell cultures erythroid is the "method of 
Fibach". It is divided into 2 phases: the first, which consists in the 
cultivation of mononuclear cells, obtained by layering with limphoprep and 
centrifugation, in the presence of various growth factors that eliminates the 
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lymphocytic component; in this way the primitive erythroid progenitors 
(BFUe) proliferate and differentiate, while other cells such as lymphocytes 
and monocytes are eliminated. In the second phase, the progenitors 
recovered from the phase in suspension and cultured in a medium 
containing erythropoietin for fourteen days, continue to proliferate and 
mature into orthochromatic normoblasts and then in erythrocytes 
enucleated. It remains, however, a significant component of lymphocytes 
(about 38% of CD45+ cells) that interferes with the analysis of erythroid 
cells. [62] In our laboratory has been optimized then a new method of 
cultivation that allows to have a pure erythroid population. To do this, we 
start from CD34 positive cells separated from monocytes and lymphocytes 
by using immune magnetic beads binding the antibody anti - CD34. Using a 
combination of growth factors and cytokines (SCF, Epo, IL-3), the 
progenitors are induced to proliferate and then differentiate. With the latter 
method is possible to reproduce all stages of erythropoiesis in 14 days, to 
obtain a large number of cells even starting from a low amount of peripheral 
blood. [58] For these characteristics, the culture protocol developed by us is 
the best method to be applied to the study of genes involved in iron 
metabolism.  
 
Our work proposes the study of ferroportin in erythroid cell cultures: 
A. in physiological conditions (or control), in cell cultures set with erythroid 
precursor from peripheral blood of healthy donors: 
During the differentiation our study confirmed what has been said in the 
literature (by Cianetti), the expression of FPN1B is very low in the early 
days of culture and increases at day 7 (pro erythroblasts) and then 
decreases again at day 14 (mature erythroblasts).  
The FPN1A has the opposite trend: is high at the precursors stage (day 0), 
then decreases at day 7 and increases again at day 14. From these results 
113 
 
is possible to speculate that the erythroid cells need a major expression of 
the isoform non-iron related at day 7, because at this stage the cells need 
iron for the haemoglobin synthesis and it is important to have an iron 
transporter sensitive to the systemic iron, not to the intracellular one. On 
the other hand, if at this stage the FPN1A would be the major isoform 
expressed, the cells could not have enough iron for the haemoglobin 
synthesis, since this isoform allows the exit of all the surplus of iron 
necessary for the heme synthesis. 
The intra and extracellular iron levels confirm the expression trade of the 
ferroportin mRNA (see Appendix, chart 1A): from day 7 to day 14 of the cell 
culture, there is a decrease of intracellular and a slight increase of 
extracellular iron. 
That is explained by the fact that the erythroid cells do not need iron 
anymore at the end of the differentiation process and there is less iron into 
the supernatant as what we would expect because the abundant part of the 
ion was used for all the biosynthetic process at the pro-erythroblast stage 
(around day 7 of differentiation). 
 
B. In thalassemic conditions in cell cultures set with erythroid precursor 
from peripheral blood of NTDT patients. 
During the thalassemic differentiation, the expression of both FPN isoforms 
follows the same trade of the control cell cultures: the FPN1B is low in the 
early days of culture and increases at day 7 (pro erythroblasts) and then 
decreases again at day 14 (mature erythroblasts).  
The FPN1A has the opposite trend: is high at the precursors stage (day 0), 
then decreases at day 7 and increases again at day 14.  
If we compared the expression of the ferroportin isoforms between the 
CTRL and NTDT differentiation, is possible to see that the FPN1B is the 
major expressed isoform in NTDT compared to the physiologic condition.  
114 
 
The intra and extracellular iron levels confirm the expression trade of the 
ferroportin mRNA (see Appendix, chart 1B): from day 7 to day 14 of the cell 
culture, there is a decrease of intracellular and a slight increase of 
extracellular iron. 
This has the same explanation given for the Control cell cultures. The 
erythroid cells do not need iron anymore at the end of the differentiation 
process; there is less iron in the supernatant as we would expect because 
the abundant part of the ion was used for all the biosynthetic process at the 
pro-erythroblast stage (around day 7 of differentiation). 
Comparing the intra and extracellular iron levels between the CTRL and 
NTDT cell cultures during the erythroid differentiation process, it is possible 
to see that both the conditions have roughly the same amount of iron 
concentration at both the intra and extracellular levels. 
 
C. In condition of iron depletion and iron overload by using DFO and FAC. 
In CONTROL cell cultures 
The results show that the conditions of iron depletion and iron overload do 
not cause a change of mRNA expression in both the FPN isoforms. 
Regarding the FAC condition, this is a confirm of what has been illustrated 
by Marro [6] In fact, they treated cultures of macrophages with FAC and the 
FPN did not show any changes in its mRNA expression; here we had the 
same result in the erythroblast cell cultures.  
The genetic analysis are confirmed by the intra and extracellular iron levels, 
if the adding of FAC does not change the FPN isoforms expression, there 
are not differences at the intracellular iron levels between the untreated and 
the FAC condition. 
The only change is in the iron levels in the supernatant, but this could be 
surely related to the amount of Ferric Ammonium Citrated that has not been 
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imported into the cells and this amount has been measured by our Iron 
assay Kit. 
 
In NTDT cell cultures 
The results show that the conditions of iron depletion and iron overload do 
not cause a change of mRNA expression in both the FPN isoforms as it has 
been already seen in the CTRL cell cultures. 
The genetic analysis are confirmed by the intra and extracellular iron levels, 
if the adding of FAC does not change the FPN isoforms expression, there 
are not differences of the intracellular iron concentration between the 
untreated and the FAC condition. 
The only change is in the iron levels in the supernatant, but this could be 
surely related to the amount of Ferric Ammonium Citrated that has not been 
imported into the cells and this amount has been measured by our Iron 
assay Kit. 
So even for the NTDT cell cultures, the iron depletion and overload do not 
influence the FPN isoforms expression nor the cellular iron content. 
 
D. In condition of free iron heme and heme iron bound by adding SnPP IX 
and hemin to the cell cultures. 
In CONTROL cell cultures 
As it has already seen for the iron depletion and overload conditions, the 
ferroportin isoforms mRNA do not show any changes under free heme and 
heme treatment. 
That is not what has been explained by Marro in mice and macrophages 
treated with SnPP IX and Hemin, since they discovered some MARE/ARE 
sequences on the FPN promoter (they did not distinguish between the two 
isoforms) responsive for the heme. [6] 
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From their results, the FPN mRNA increased under heme exposure, in our 
erythroblasts cell cultures the amount of FPN mRNA (both isoforms) is the 
same in conditions treated with Hemin or SnPP IX. 
The only explanation could be that the MARE/ARE sequences (MAF 
Recognition Elements / Antioxidant Response Elements) are tissue – 
specific, that means they are present only on the macrophages promoters; 
or we need to improve the number of our experiments and see what 
happens next. 
As there is no difference in the FPN expression, even the intracellular iron 
levels remain the same compared to the untreated condition. The only 
change can be observed in the extracellular iron: the SnPP IX conditions 
show a decrease in iron concentration that could be related to the fact the 
SnPP IX is heme without iron and when this compound enters into the cells  
in order to participate to the heme biosynthesis, the cells need iron to 
bound to the protoporfirins and make heme. To do that, the cells have to 
take iron from the extracellular environment, that is the reason why the 
amount of iron into the supernatant of SnPP IX conditions is lower 
compared to the untreated one. 
 
In NTDT cell cultures 
The ferroportin isoforms do not change their expression if the cell cultures 
are treated with both Protoporfirin IX and Hemin at different concentrations, 
compared to the untreated condition. Those are similar result as the 
CONTROL cell cultures. 
Regarding the iron concentrations, the intracellular iron level decreases in 
the treated conditions compared with the untreated one. This is not 
reflecting the FPN expression, so it is important to repeat the experiment in 
order to have more data and try to see if there is some modulation of the 
intracellular iron content by adding those compounds or not in the NTDT 
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cell cultures.  The extracellular iron levels show no much difference 
between the untreated and the SnPP IX conditions, while a big change is 
notable between the control and the Hemin conditions where is possible to 
see a marked increase of iron present into the cell culture supernatant. The 
situation is different from the FAC condition previously described since the 
kit cannot measure the iron bound to different proteins such as heme. That 
could be related to a heme degradation in the extracellular environment, 
releasing the free iron and this one could be measured by the kit. 
  
E. In condition of oxidative stress by adding hydrogen peroxide 0.1mM at 
the control cell cultures. 
There are many papers explaining the high presence of ROS production in 
the beta thalassemia due to the Fenton’s reaction caused by the iron 
overload. [63][64][65] 
This lead us to further investigate the role of the oxidative stress in the 
erythropoietic process and if the ROS could be the responsive element for 
the ferroportin isoform 1B expression. 
We tried to simulate a situation of oxidative stress in the control cultures by 
adding hydrogen peroxide and then we studied the mRNA of both isoforms 
to see if something has changed in their expression. 
Something did change, in fact, the condition treated with H2O2 shows an 
increase of the FPN1B expression and a decrease of the FPN1A isoform 
compared with the untreated condition. Even the intra and extracellular iron 
levels follow the genetic expression of the protein: an increase of the 
FPN1B is related with an increase of iron export from the cell to the 
supernatant, showing an increase of extracellular iron in condition under 
oxidative stress compared to the untreated.  
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CONCLUSIONS 
In conclusion, it can be said that the method defined by our lab was optimal 
for the study carried out and new results unknown up to now have been 
obtained.  
To have a complete view of all the work will be necessary to define some 
macrophage cultures in which the expression and production of Ferroportin 
1A and 1B in the same condition of the erythroid cultures will be studied.  
It will also be of great importance alongside the results obtained in this 
work, with an analysis of the Ferroportin by the technique of Western – Blot 
in order to study in deep if the oxidative stress could influence the amount 
of translate protein and not only the mRNA expression. The problem of this 
technique is that the ferroportin isoforms are the same once translated, so 
the western blot could not distinguish between the FPN1A and 1B, 
however, it could be also useful to determine the amount of the protein 
produced. We have to define other techniques in order to find the proper 
one that could discriminated between the production of the two isoforms. 
It could be also interesting moving from the ex vitro to an in vivo contest by 
using wild type and thalassemic mice models in order to be able to study 
the large pathway of iron and heme metabolism and have a major 
comprehension of all the mechanisms elapsing and the differences 
between the expression of the FPN1A and 1B isoforms in different cellular 
compartments. 
The last, but not least, is try to confirm the results obtained in the control 
cultures by using the NTDT cells. We have to set a panel of minimum three 
NTDT cell cultures and treat them with hydrogen peroxide and see if the 
FPN1B will behave in the same way as the CTRL one. This will be the 
confirm that the major expression of the FPN1B during all stages of the 
erythroid differentiation in NTDT compared to the CTRL is due to the fact 
that the NTDT patients have a major level of ROS compared to the healthy 
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subjects and the oxidative stress could be the responsive factor of the 
FPN1B expression. 
Discover how the ferroportin is regulated in the NTDT contest could help us 
to think about and define new therapy strategies not only oriented to the 
hepcidin itself, but involving the ferroportin as well. 
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APPENDIX 
 
 
Chart 1: mRNA expression (2
-dCt
) of both ferroportin isoforms in CTRL and NTDT during 
erythroid differentiation  
 
From the chart is possible to see at day 7 of CTRL (1A) and NTDT (1B) cell 
differentiation a decrease of both FPN isoforms expression compared to 
day 0. At day 14, there is an increase of the FPN1A and 1B compared to 
day 7 for both CTRL and NTDT conditions.  
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